  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 1 of 60 CONFIDENTIAL  
The Vivaer ® Procedure for Treatment of the Septal  Swell Bodies  for 
Airway Obstruction - A Prospective Open -Label Multicenter Study 
(SWELL)  
Protocol Number: CTP1125 
Protocol Date: 27 Jul 2021 
Amendment Date:  31 Aug 2021 
Version : C 
Principal Investigator:  Jordan Pritikin, MD 
Chicago Nasal & Sinus Center  
111 W Washington Street, Suite 903  
Chicago, IL 60602 
Phone: (312)-372-9355 Email: jpritikinmd@gmail.com
 
Sponsor: Aerin Medical, Inc.  
232 E. Caribbean Drive Sunnyvale, CA 94089 USA  
 Contact: An ais Laborde , Senior Director of Clinical Affairs
 
Phone: 650-518-9624 Email: alaborde@aerinmedical.co m
   
Sponsor  
Representative:  <If the sponsor is not a resident in the country(ies) in which the clinical 
investigation is to be carried out, the name and address of a representative in that country (those countries) can be required according to national or regional 
regulations>  
 INVESTIGATOR  
I, the undersigned, certify that I have reviewed this Clinical Investigational Plan and agree to abide by the terms of the study described herein and within the Investigator Agreement, Clinical Trial Agreement and 
according to the Declaration of Helsinki and The Belmont Report as well as any conditions imposed by the 
reviewing Institutional Review Board, Ethics Committee, U.S. FDA or other regulatory agency.  
Site Name:   
Print Name:   
Signature:   Date:   
 
This protocol contains proprietary and confidential information of Aerin Medical, Inc.  and should be restricted in its 
distribution to investigators, subinvestigators, and reviewing Institutional Review Boards/Ethics Committees .  Do not 
copy, distribute, or share with others without prior written authorization from Aerin Medical Inc.  
  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 2 of 60 CONFIDENTIAL  
Table of Contents  
 
Protocol Summary  .................................................................................................................... 5  
Activity / Assessment  ...................................................................................................... 9  
Screening .......................................................................................................................... 9  
Treatment  ......................................................................................................................... 9  
Follow-up ......................................................................................................................... 9  
(in-office) ......................................................................................................................... 9  
Extended Follow-up (remote) .......................................................................................... 9  
List of Abbreviations .............................................................................................................. 10  
1.0 Introduction and Background ........................................................................................ 12  
2.0 Purpose ........................................................................................................................... 14  
2.1 Device and Regulatory Status  ............................................................................... 14  
2.2 Indications for Use  ................................................................................................. 14  
2.3 Rational  ................................................................................................................... 14  
3.0 Device and Procedure Description  ................................................................................. 14  
4.0 Study Objectives ............................................................................................................ 16  
4.1 Primary Objective  .............................................................................................. 16  
4.2 Secondar y Objective  .......................................................................................... 17  
5.0 Study Plan ...................................................................................................................... 18  
5.1 Study Design ...................................................................................................... 18  
5.2 Study Population ................................................................................................ 18  
5.2.1  Inclusion Criteria  .....................................................................................19  
5.2.2  Exclusion Criteria  ....................................................................................19  
5.3 Study Entry and Enrollment ............................................................................... 20  
5.4 Outcome Measures ............................................................................................. 20  
5.4.1  Nasal Assessment  .....................................................................................20  
5.4.2  CT Assessment – Substudy – Selected Sites Only  .................................21  
5.4.3  Nasal Obstruction Symptom Evaluation (NOSE) Scale  .......................22  
5.4.4  Visual Analog Scale (VAS) for Nasal Pain ............................................22  
5.4.5  Ease of Breathing Through the Nose – Numeric Rating Scale 
(NRS) Breathing Score  ............................................................................22  
5.4.6  Sino -Nasal Outcomes Test 22 (SNOT -22) ..............................................23  
5.4.7  Participant Satisfaction Ass essment  .......................................................23  
5.4.8  Medications for Symptoms of Nasal Obstruction  .................................23  
5.4.9  Adverse Events  .........................................................................................24  
5.5 Success/ Failure Criteria  ..................................................................................... 24  
5.5.1  Participant Success  ..................................................................................24  
5.5.2  Study Success  ............................................................................................24  
5.6 Duration of the Study  ......................................................................................... 24  
5.7 Site Staffing and Responsibilities of Study Personnel ....................................... 24  
5.8 Risk/Benefit Analysis  ........................................................................................ 25  
5.8.1  Risks  ..........................................................................................................25  
5.8.2  Potential Risks to Participant Confidentiality  ......................................26  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 3 of 60 CONFIDENTIAL  
5.8.3  Mitigation of Risks  ...................................................................................26  
5.8.4  Study Justification in Relation to Risk ...................................................27  
5.8.5  Benefits  ......................................................................................................27  
6.0 Study Schedule and Procedures ..................................................................................... 27  
6.1 Schedule of Events  ......................................................................................................... 28  
Activity / Assessment  .................................................................................................... 28  
Screening ........................................................................................................................ 28  
Treatment  ....................................................................................................................... 28  
Follow-up ....................................................................................................................... 28  
(in-office)  ....................................................................................................................... 28  
Extended Follow-up (remote) ........................................................................................ 28  
6.2 Participant Flowchart  ......................................................................................... 29  
6.3 Enrollment and Screening Assessment  .............................................................. 29  
6.4 Treatment Visit and Procedure (Day 0) ............................................................. 31  
6.5 Postprocedure Assessments and Care  ................................................................ 34  
6.6 Follow-up Evaluations and Study Exit .............................................................. 34  
6.7 Product Handling and Accountability ................................................................ 36  
7.0 Statistical Considerations  ............................................................................................... 36  
7.1 Study Design ...................................................................................................... 36  
7.2 Study Hypotheses............................................................................................... 37  
7.3 Power Analysis and Sample Size Estimate  ........................................................ 37  
7.4 Timing of Analysis  ............................................................................................ 38  
7.5 Analysis Populations .......................................................................................... 38  
7.6 Missing Data ...................................................................................................... 39  
7.7 Pooling ............................................................................................................... 39  
7.8 Participant Dispos ition ....................................................................................... 39  
7.9 Demographics and Baseline Characteristics  ...................................................... 39  
7.10  Primary Endpoint Analysis  ................................................................................ 39  
7.11  Secondary Endpoint Analysis ............................................................................ 39  
7.12  Other Outcome Measures Analyses  ................................................................... 40  
7.13  Subgroup Analysis  ........................................................................................... 41  
7.14  Safety Analysis  ................................................................................................. 41  
7.15  Follow-up Phase Analysis.................................................................................. 42  
7.16  Standard Methods of Report .............................................................................. 42  
8.0 Adverse Events and Product Complaints / Device Deficiencies ................................... 42  
8.1 Adverse Events .................................................................................................. 42  
8.1.1  Definitions  .................................................................................................42  
8.1.2  Documentation and Reporting of Adverse Events  ................................45  
8.2 Product Complaints / Device Deficiencies  ........................................................ 46  
8.2.1  Definitions  .................................................................................................46  
8.2.2  Documentation and Reporting of Complaints / Device 
Deficiencies  ...............................................................................................46  
9.0 Study Administration ..................................................................................................... 46  
9.1 Investigator Training  .......................................................................................... 47  
9.2 Study Monitoring ............................................................................................... 47  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 4 of 60 CONFIDENTIAL  
9.3 Documentation of Study Findings ..................................................................... 48  
9.3.1  Data Management ....................................................................................48  
9.3.2  Case Report Forms  ..................................................................................48  
9.3.3  Inve stigator Responsibilities, Records, and Reports  ............................50  
9.3.4  Retention of Study Records .....................................................................52  
9.3.5  Data Quality Assurance ...........................................................................52  
9.3.6  Confidentiality  ..........................................................................................52  
9.3.7  Publication Policies  ..................................................................................53  
9.4 Study Suspension or Early Termination ............................................................ 53  
10.0  Ethics .............................................................................................................................. 54  
10.1  Institutional Review Board  ................................................................................ 54  
10.2  Ethical Conduct of the Study ............................................................................. 54  
10.3  Participant Privacy  ............................................................................................. 54  
10.4  Participant Insurance  .......................................................................................... 55  
10.5  Participant Reimbursement  ................................................................................ 55  
10.6  Participant Withdrawal  ...................................................................................... 55  
10.7  Protocol Modifications....................................................................................... 55  
10.8  Protocol Adherence and Deviations  ................................................................... 56  
10.8.1  Definition  ..................................................................................................56  
10.8.2  Documentation and Reporting of Deviations ........................................56  
11.0  References  ...................................................................................................................... 57  
 
  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 5 of 60 CONFIDENTIAL  
Protocol Summary 
Title:  The Vivaer® Procedure for Treatment of the Septal Swell Bodies  for 
Airway Obstruction  - A Prospective Open -Label Multicenter Study 
(SWELL)  
Purpose:  The purpose of this study  is to assess the clinical use of the Vivaer ARC 
Stylus to treat Septal Swell Bodies ( SSB) to improve symptoms in adults 
diagnosed with nasal obstruction attributed to SSB .  
Indications 
for Use:   The Vivaer ARC Stylus  is indicated for use in otorhinolaryngology 
(ENT) surgery for the coagulation of soft tissue in the nasal airway, to 
treat nasal airway obstruction (NAO) by shrinking submucosal tissue, 
including cartilage in the internal nasal valve area.  
The Aerin Conso le is an electrosurgical system intended to generate 
radiofrequency electrical current for the use of an Aerin Medical Stylus. The Aerin Console is indicated for use in small clinic, office or hospital environments. 
Study 
Objective s: The primary objective of this study is to determine the efficacy of treating 
the nasal septal swell body area with temperature -controlled 
radiofrequency (RF) using the Vivaer system for the treatment of NAO.  
The  secondary objective is to evaluat e the dur ability of the treatment 
effect in an extended follow -up period of 36 months. . 
Study Design:  The study is designed as a multicenter , prospective, open -label, single -
arm study. 
All participants will be evaluated prior to treatment and following 
treatment at week 1 and week 13 (3 months). The 3- month evaluation will 
be used for the primary endpoint analysis. 
The study will have an extended follow -up phase with evaluations 
conducted at 26 weeks (6 months), 52 weeks (12 months), 104 weeks (24 months) and 156 weeks (36 months) to provide additional information on longer- term efficacy and duration of treatment effect.  
A subset of study sites will be selected to participate in a substudy of the use of computed tomography (CT) imaging to assess changes in the SBB after treatment.  
Vivaer  
Treatment : The Vivaer procedure will be performed in the study clinic using the 
Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a 
disposable handheld device capable of delivering bipolar radiofrequency energy to t
issue when connected to the Aerin Console radiofrequency 
generating device. Participants will undergo bilateral treatment of the 
nasal airway in a single study procedure session. Each side of the nose will be treated as follows:  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 6 of 60 CONFIDENTIAL  
• Two (2) to six (6) nonoverlapping applications of RF energy 
are performed at the SSB per nostril.  
The default treatment settings will be used for the study: temperature 60 ° 
C, power 4 watts, treatment time 18 seconds, and cooling time 12 
seconds. No repeat (“touch up”) proc edures will be permitted after the 
initial procedure through the end of the study (36 months). 
 
Primary 
Endpoint:  The primary endpoint is improvement in self -reported Nasal Obstruction 
Symptom Evaluation (NOSE) Scale score from baseline recorded at the 
screening evaluation  to 13 weeks after the procedure.  
Secondary 
Endpoints:  • Responder percent: A responder is defined as at least 1 NOSE Scale 
class improvement or an improvement (decrease) in NOSE Scale 
score of 20% or more from  baseline to 13 weeks after the procedure.  
• Frequency of device -related and procedure -related serious adverse 
events , including frequency of septal perforation during the 
procedure, through the 3- month evaluation.  
Study 
Hypotheses  Primary hypothesis: mean improvement in NOSE Scale score from 
screening  to 13 weeks will exceed 25 points.  
Other hypothesis: the treatment effects will be maintained through the 
extended follow -up period of 36 months. 
Other 
Outcome 
Measures:  Adverse Events  - Incidence (type and category) of adverse events overall 
and by follow- up interval.  
Nasal Assessment  - The target  SSB within each nostril will be visually 
assessed at screening, prior to the procedure , immediately after the 
procedure, and 3 months after the procedure. The use of an endoscope for 
visual assessment is required.  Representative endoscopic video of each 
nasal passage will be captured for each assessment. Endoscopic nasal 
assessment will incl ude assignment of an SSB grading score.36CT 
Assessment  - A subset of study sites will be selected to participate in a 
substudy of the use of computed tomography (CT) imaging to assess 
changes in the SBB after treatment.  Radiographic c hanges, including 
change in size of the SSB, will be assessed using CT imaging prior to the procedure and at 3 months after the procedure.  
NOSE Scale Score:   
• Mean and mean change from screening at the 3 -, 6-, 12-, 24- and 
36-month follow -up evaluations. 
• Distribution of NOSE Scale score severity categories (mild, 
moderate, severe, extreme) at the 3 -, 6-, 12- , 24- and 36-month 
follow -up evaluations. 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 7 of 60 CONFIDENTIAL  
• Mean, change from screening in mean, and response distribution 
of the 5 components of the NOSE S cale score (nasal congestion, 
nasal blockage, trouble breathing, trouble sleeping, and getting 
enough air during exercise) at the 3 -, 6-, 12- , 24- and 36-month 
follow -up evaluations. 
• Proportion of responders based on improvement in NOSE Scale 
score at the 3-, 6-, 12-, 24 - and 36-month follow-up evaluations. 
Visual Analog Scale (VAS) for nasal pain - perception of pain associated 
with the procedure on a 0 to 100 mm scale (0 indicating no pain and 100 
indicating the worst pain ever) assessed immediately after treatment and at 1 week . 
Numerical Rating Scale (NRS) for ease of breathing through the nose  - 
perception of the ability to breathe through the nose over the past week on a 0 to 10 scale (0 indicating no difficulty and 10 indicating sever e 
difficulty) assessed at screening, 3, 6, 12, 24 and 36 months.  
Sino-Nasal Outcome Test (SNOT -22) - Participant -reported outcome 
measure for the prior 2 weeks of 22 symptoms related to both nasal and general health on a score of 0 (no problem) to 5 (problem as bad as it can 
be) and indicate up to 5 items they consider the most important items 
affecting their health. Scores range from 0 to 110, with higher numbers representing a significant problem for the participant.  
Participant Satisfaction Assessment  - Five-question self -reported survey 
of satisfaction with the procedure and recommendation to others 
administered at the 3 -, 6-, 12-, 24- and 36-month follow- up evaluations.  
Medications - M edication  used for relief or treatment of NAO symptoms 
will be docum ented at screening  and updated as necessary with new 
associated medications at each postprocedure evaluation through the End 
of Study visit . An increase, decrease, no change, starting new or stoppage 
of medication use compared to the first recorded use will be documented.  
Length of 
Study:  The primary outcome will be evaluated at 3 months . In addition, 
evaluations at 6, 12, 24 and 36 months after treatment will extend follow-
up to 3 years for evaluation of longer -term efficacy.  Enrollment is 
anticipated to be completed within 6 months. Therefore , total study 
duration is anticipated to be approximately 42 months. 
Study 
Centers:  up to 10  
 
Participants:  up to 70  
 
Inclusion 
Criteria:  1. Age 22 to 85 years (inclusively) . 
2. Seeking treatment for nasal  obstruction and willing  to undergo 
an office -based procedure. 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 8 of 60 CONFIDENTIAL  
3. Baseline  NOSE score ≥ 55. 
4. Presence of SSB hypertrophy limiting visualization of the middle 
turbinate (MT ) by more than 50%.  
5. Reduction in size of the SSB  after application  of topical 
decongestant on a cotton plug directly to the SSB  region.  
6. Improvement in the symptoms of nasal obstruction after SSB 
decongestion suggesting that the SSB  may play a role in nasal 
obstruction. 
7. Willing and able to withhold anticoagulant medications during 
the perioperative period (3-day window on either side).  
8. Willing and able to provide informed consent.  
9. Willing and able to comply with the p articipant -specific 
requirements outlined in the stud y protocol.  
 
Exclusion 
Criteria:  1. Rhinoplasty, septoplasty, inferior turbinate (IT) reduction, or 
other surgical nasal procedures within the preceding 6 months. 
2. Severe case of any of the following: septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be the primary contributor to the participant’s nasal obstruction symptoms and warranting surgical intervention .  
3. Any adjunctive surgical nasal procedure planned on the same day or within 3 months after the Vivaer procedure.  
4. Known or suspected allergies or contraindications for any 
general or local anesthetic agents.  
5. Known or suspected to be pregnant or is lactating.  
6. Participating in another clinical research study . 
7. Other medical conditions which in the opinion of the investi gator 
would predispose the participant to poor wound healing or 
increased surgical risk, or poor compliance with the requirements of the study. 
8. Known or suspected regular use of oxymetazoline (Afrin) nasal decongestant or oral steroids.  
9. For sites participating in the CT substudy only: Active sinus 
condition (eg, significant sinus diseases, infection or polyp 
formation) identified by CT.  
   
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 9 of 60 CONFIDENTIAL  
SCHEDULE OF EVENTS  
 
 
 
Activity / Assessment  
Screening  Treatment Follow -up  
(in-office) Extended Follow -up 
(remote) Preprocedure  
Procedure  
Immediate 
Postprocedur e 
1 Week  
3 Months  
(13 weeks)  
6 Months  
(26 weeks) 
12 Months  
(52 weeks)  
24 Months  
(104 weeks)  
36 months  
(156 weeks)  
 Window (days)  (-30) (0) (± 3) (± 14) (± 30) (± 30) (± 30) (± 30) 
Eligibility  X          
Consent  X          
Demographics / Medical History X          
Physician Evaluations            
Nasal Assessment ( visual , 
endoscopic) X X1  X X X     
CT imaging of SSB X2     X     
Current m edication use (study 
relevant)  X   X3 X X X X X X 
Participant Evaluations   
NOSE Scale  X4     X5 X X X X 
VAS nasal pain     X X      
NRS  ease of breathing  X     X X X X X 
Participant Satisfaction Survey       X X X X X 
SNOT -22 X     X X X X X 
Study Procedure (includes 
anethesia)    X        
Adverse Events  X   X X X X X X X 
 
1 Nasal Assessment do not need to be repeated if Screening and Treatment visits occur on the same day . 
2CT should only be performed  if your site was selected for the CT substudy and  only after all other screening procedures and 
participant eligibility is confirmed.  
3Add any postprocedure medications to the medication log . 
4Baseline NOSE Scale Score for analysis is defined as the Screening score.  
5Primary analysis endpoint  evaluation.  
 
  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 10 of 60  CONFIDENTIAL  
List of Abbreviations 
ADE – Adverse Device Effect  
AE – A dverse Event 
BMI – Body Mass Index 
CFR – Code of Federal Regulations CPAP – Continuous Positive Airway Pressure  
CRF (eCRF) – Case Report Form  (electronic Case Report Form)  
CT (CAT) – Computed Tomography (Computed Axial Tomography) 
CTA – Clinical T rial A greement  
DICOM – Digital Imaging and Communication in Medicine EDC – Electronic D ata Capture 
ENT – Ear, Nose, Throat; medical field of otorhinolaryngology (otolaryngology) FDA – Food and Drug Administration 
FDAAA – Food and Drug Administration Amendments Act 
FOV – Field of View  
FWA – Federal Wide Assurance for the Protection of Human Participants  
GCP – Good Clinical Practice  
HIPAA – Health Insurance Portability and Accountability Act 
ICH – International Council for  Harmonization  of Technical Requirements for 
Pharmaceuticals for Human Use  
ICMJE – International Committee of Medical Journal Editors  
IFU – Instructions for Use  
IRB – Institutiona l Review Board 
ISO – International Organization for Standardization  
IT – Inferior Turbinate  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 11 of 60  CONFIDENTIAL  
KVp – kilovotage peak 
MPR – Multiplanar reformation  
MRI – Magnetic Resonance Imaging  
MT – Middle Turbinate NAO – Nasal Airway Obstruction  
NOSE – Nasal Obstruction Symptom Evaluation  Scale  
NRS – Numeric Rating Scale  
SSB – Septal Swell Body  
OTC – Over-The-Counter (nonprescription) QOL – Quality of Life  
RF – Radiofrequency RFTR – Radiofrequency turbinate reduction  
SAE – Serious A dverse Event 
SADE – Serious Adverse Device Effect  
SD – standard deviation 
SNOT -22 – Sino-Nasal Outcomes Test 22  
UADE – Unanticipated A dverse Device Effect  
ULC – Upper Lateral Cartilage  
US – United States  
VAS – Visual Analog Scale  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 12 of 60  CONFIDENTIAL  
1.0 Introduction and Background 
Nasal airway o bstruction (NAO) is a highly prevalent disorder that affects the upper 
airway system causing restriction in normal airflow into the nasal cavity. Chronic nasal 
obstruction can elicit many symptoms, including congestion, stuffiness, headache, fatigue, sleep disturbance, daytime sleepiness, snoring and impairment of various daily and social activities leading to an overall decline in health -related quality of life 
(QOL).
1-3 Given its high prevalence, treatment of  NAO can be costly, with 
expenditures for prescriptions, over -the-counter (OTC)  medications, and doctor’s 
visits.  
NAO  can be mediated  by a diversity of mucosal and structural disorders in the nasal 
cavity , including acute or chronic mucosal inflammation from infection, allergenic or  
non-allergenic irritants, or structural factors such as nasal masses or polyps, turbinate 
or septal swell body (SSB)  hypertrophy, nasal septal deviation, and nasal valve angle 
changes, narrowing or collapse.1,4-8 
Treatment strategies for NAO have included both noninvasive management and surgical treatment with recent focus on treatment of the nasal valve region.  The nasal 
valve is defined by the caudal cartilaginous nasal septum, the anterior head of the inferior turbinate (IT ), and the caudal end of the upper lateral cartilage  (ULC) . This 
region is critic al in the development of nasal obstruction and represents the narrowest 
part of the nasal airway.
3,8-10 As described by Poiseuille’s law, minute changes in the 
diameter of a tube will result in exponential changes in airflow11. Thus, any narrowing 
in the nasal valve region, such as that associated with septal  deviation, turbinate 
hypertrophy, congestion of SSB , ULC collapse or insufficiency, nasal polyps, or 
structural changes after rhinoplasty, will change nasal breathing.11  
Multiple devices designed to increase the size of the nasal passage at the nasal valve area are available OTC for n oninvasive management of NAO.  These products are 
marketed to people with poor nasal breathing, snoring difficulties, and  those with 
increased breathing demands, such as athletes. These devices include adhesive external 
nasal dilator strips and internal nasal dilators. Both internal and external dilators have 
been found to effectiv ely dilate the nasal airway and reduce airway resistance.
12-15 
However, nasal dilating devices require significant patient involvement and 
compliance to be effective. 
Surgical treatment most commonly consists of repair of a deviated nasal septum and reduction of the IT . Surgical treatments may involve various suturing techniques used 
alone or in conjunction with grafting techniques using autologous cartilage typically 
harvested from the nasal septum or ear or synthetic biomaterials.
9,16-19 A new 
minimally invasive surgical procedure has also been introduced that uses an absorbable 
polymer  blend nasal implant to support the upper and lower cartilage inside the lateral 
nasal wall similar to more traditional cartilage and nonabsorbable polymer grafts.20 
Surgical treatments  are efficacious, but may require  significant recovery periods with 
complication  risks  such as bleeding, intranasal adhesions, scarring, infection, and graft 
migration, resorption or extrusion.16,19  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 13 of 60  CONFIDENTIAL  
Radiofrequency (RF)  energy has been used for decades in the fields of 
otorhinolaryngology (ENT), neurosurgery, cardiology, urology, and general surgery. 
ENT surgeons currently use radiofrequency energy in several nasal therapies. 
Numerous studies have demonstrated that radiofrequency therapy applied to tissue of the nasal passage can be safe and effective in improving nasal obstruction while preserving nasal function.
21 Radiofrequency turbinate reduction (RFTR), for instance, 
is a minimally invasive surgical option that can reduce tissue volume in a precise, targeted manner.  This technique uses radiofrequency to create heat within the 
submucosal tissue of the turbinate, reducing tissue volume with minimal impact on surrounding tissues. Radiofrequency turbinate reduction differ s fundamentally from 
traditional surgical methods by using low -power radiofrequency energy to provide a 
relatively quick and painless treatment for tissue coagulation and/or ablation .
22,23 There 
have been multiple studies analyzing the safety and outcomes of RFTR treatment. A systematic literature review of the RF ablation technique concluded that the technique is well tolerated and effective.
24  
Targeted radiofrequency heating of the lateral cartilaginous nasal wall has also been used in patients with inspiratory nasal valve collapse.  
25,26 The Seren procedure25 used 
an incisional  approached to apply RF heating to the target tissue with the intent to 
produce tissue retraction and volume reduction. Significant improvement in Nasal Obstruction Symptom E valuation (NOSE) Scale score was seen at 16 weeks. The 
Vivaer procedure
26 applies radiofrequency energy along with outward pressure to the 
mucosa at  the region of the caudal  end of the weakened ULC to induce mechanical 
deformation and potentially change the shape of the lateral nasal wall . At 6 months , 
mean NOSE S cale score improved to 24.7 (SD 20.4, range 0- 90) with an average 
decrease of 54.5 (68.6%). I mprovement in mean NOSE S cale score was maintained 
through the 12-, 18-, and 24- month evaluations (27.6, 32.7, and 26.8, respectively).27  
As discussed above, typical medical, surgical, or radiofrequency treatments of nasal obstruction target the  nasal septum, IT  or nasal valve cartilage. However, SSB s also lie 
within the nasal airflow pathway and may be contributors to obstructed flow.
10,28,29, but 
only minimal attention has been paid to them historically and few studies describe them . The SSB have also been referred to as septal turbinate, nasal swell bodies, 
Kiesselbach’s ridge, septal body, and septal tumescence since first being described by Wustrow.
30 The SSB can be identified on rhinoscopy, endoscopy, and by computed 
tomography ( CT) and magnetic resonance imaging ( MRI), appearing as a widened 
portion of the anterior nasal septum. The SSB  contains both glandular and vasoerectile 
tissues although the function of the SSB  is not well described.10 A study of MRI brain 
studies from 54 patients with nonsinonasal complaints provided measures of the 
average length, width, and height of the SSB  and further described them  as a normal 
2x3-cm fusiform structure located anterior to the middle turbinate (MT) and superior 
to the IT approximat ely 2.5 cm above the nasal floor31 The study also concluded that 
the proximity of the SSB  to the nasal valve region in conjunction with its composition 
of a large number of venous sinusoids suggest ed a role in nasal airflow regulation. The 
SSB has been found to be more prominent contralateral to a septal deviation32 and to 
be significantly larger among patients with allergic rhinitis and rhinosinusitis than in 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 14 of 60  CONFIDENTIAL  
control patients without those conditions.33 The SSB are known to swell in the presence 
of histamine.34 A decrease in the size of the anterior nasal septum after application of a 
topical decongestant has been observe d through MRI.35  Preliminary studies indicate 
that radiofrequency energy can be used to reduce swell body size.36,37 
2.0 Purpose   
The purpose of this study  is to assess the clinical use of the Vivaer ARC Stylus  to treat 
Septal Swell Bodies ( SSB) to improve symptoms in adults diagnosed with nasal 
obstruction.  
2.1 Device and Regulatory Status  The Vivaer  procedure will be performed in the study clinic  using the Vivaer ARC 
Stylus and Aerin Console . The Vivaer ARC Stylus  is a disposable handheld device 
capable of delivering bipolar radiofrequency energy to tissue when connected to the 
Aerin Console radiofrequency generating device  with temperature control capable of 
delivering very low doses of energy.  
The Vivaer ARC Stylus  was cleared for use in the United States (U.S.) by the Food and 
Drug Administration (FDA ) under 510(k) K172529 and the Aerin Console was cleared 
under 510(k) K162810. 2.2 Indications for Use The Vivaer ARC Stylus  is indicated for use in otorhinolaryngology (ENT) surgery for 
the coagulation of soft tissue in the nasal airway, to treat nasal airway obstruction 
(NAO)  by shrinking submucosal tissue, including cartilage in the internal nasal valve 
area.  
The Aerin Console is an electrosurgical system intended to generate radiofrequency electrical current for the use of an Aerin Medical Stylus. The Aerin Console is indicated for use in small clinic, office,  or hospital environments.  
2.3 Rational  
Patients suffering from symptoms attributed to NAO  primarily due to internal nasal 
valve dysfunction, rather than hypertrophied turbinates, have treatment options ranging 
from OTC devices and medications to surgical procedures that have varying degrees of effectiven ess, discomfort, and potential complications. There remains a significant 
need for a simple, safe, nonsurgical, minimally invasive treatment that can provide sustained relief for patients suffering with symptoms of NAO. The Viv aer procedure 
using RF technology has been shown to be safe, effective , and durable in a single -arm 
trial comparing pretreatment condition with posttreatment condition. This study is being undertaken to provide additional evidence of the effectiveness of the procedure when treating th e SSB  tissue.   
3.0 Device and Procedure Description  
The Vivaer ARC Stylus  (Figure 1) consists of a handle, shaft and treatment tip. An 
array of bipolar electrodes is positioned on a nonconductive tip ( Figure 2 ) that is 
attached to the handle via a nonconductive shaft. A temperature sensor is located on 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 15 of 60  CONFIDENTIAL  
the Stylus tip to monitor tissue temperature during RF energy delivery. The Stylus is 
powered by an external temperature -controlled radiofrequency generator via a flexible 
cable ( Figure 3 ). The Stylus incorporates features to allow compatibili ty with and 
authentication by only the Aerin Console. The connector for the Vivaer ARC Stylus  
has a pin configuration that prevents its use with other RF generators, making it only compatible with the Aerin Console. Authentication of the Stylus is achieved via a 
crypto chip that is built into the Stylus handle assembly. The chip is read and written to by the Aerin Console. Information stored on the chip includes the Stylus model information, treatment parameters, usage timestamp data, and a count of the remaining treatment cycles (based upon preset maximum).  
  
 
Figure 1.  Vivaer ARC Stylus  
 
  
 
Figure 2.  Vivaer ARC Stylus  Tip 

  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 16 of 60  CONFIDENTIAL  
 
Figure 3.  Aerin Console with Vivaer ARC Stylus  
The Vivaer ARC Stylus  is temporarily inserted into the nose to access the treatment 
area. The Stylus requires the application of conductive media (eg, saline gel) to the tip 
prior to use. The conductive media helps to ensure good contact with tissue at all points of the treatment tip to facilitate energy transmission. Application of the RF energy is controlled by a foot switch connected to the Aerin Console. The Vivaer ARC Stylus  
improves nasal breathing by modifying the tissues of the nasal airway using low doses of radiofrequ ency energy. The low -power RF energy generates heat within the tissue 
and creates a coagulation lesion. As the lesion heals, the tissue retracts and stiffens, thereby decreasing NAO and improving airflow.  
The procedure requires local anesthesia only. The Stylus is manufactured and supplied 
sterile and for single use only by Aerin Medical and may be used to treat both nostrils of the participant.  
4.0 Study Objectives  
4.1 Primary Objective  
The primary objective of this study is to determine the efficacy of treating the nasal septal swell body area with temperature -controlled radiofrequency (RF) using the 
Vivaer system for the treatment of NAO.  
The primary objective will be assessed through evaluation of the primary endpoint, 
defined as change in mean participant NOSE Scale score at 3 months after the 
procedure, and the secondary endpoints of responder percent at 3 months and frequency of septal perforation, and other device -related and procedure -related 
seriou s adverse events through 3 months. 

  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 17 of 60  CONFIDENTIAL  
4.2 Secondary Objective  
The secondary objective is to evaluat e the durability of the treatment effect in an 
extended follow -up period of 36 months.  
In addition to the primary and secondary endpoints, both the primary and secondary 
objectives will be supported by assessment of several other effectiveness and s afety 
measures that will include: 
• Adverse events  - Incidence (type and category) of adverse events overall 
and by follow- up interval.  
• Nasal Assessment  - The target  SSB within each nostril will be visually 
assessed at screening, prior to the procedure , immediately after the 
procedure, and 3 months after the procedure . The use of an endoscope for 
visual assessment is required.  Representative endoscopic video of each 
nasal passage will be captured for each assessment . Endoscopic n asal 
assessment will include assignment of an SSB grading score.36 
• CT Assessment  – A subset of study sites will be selected to participate in a 
substudy of the use of CT imaging to assess changes in the SBB after 
treatment. Radiographic changes, including change in size of the SSB , will 
be assessed using CT imaging prior to the procedure  and at 3 months  after 
the procedure. 
• NOSE Scale score:   
o Mean and mean change from screening at the 3 -, 6-, 12-, 24- and 
36-month follow -up evaluations. 
o Distribution of NOSE Scale score severity categories ( mild, 
moderate, severe, ext reme ) at the 3- , 6-, 12- , 24- and 36-month 
follow -up evaluations. 
o Mean, change from screening  in mean, and response distribution of 
the 5 components of the NOSE Scale score (nasal congestion, nasal blockage, trouble breathing, trouble sleeping, and getting enough air 
during exercise) at the 3 -, 6-, 12- , 24- and 36 -month follow -up 
evaluations. 
o Proportion of responders based on improvement in NOSE Scale score at the 3-, 6-, 12-, 24 - and 36-month follow-up evaluations. 
• Visual Analog Scale (VAS) for nasal pain - perception of pain associated 
with the procedure on a 0 to 100 mm scale (0 indicating no pain and 100 indicating the worst pain ever) assessed immediately after treatment and at 
1 week . 
• Numeric Rating Scale (NRS)  for ease of breathing  through the nose  - 
perception of the ability to breathe through the nose over the past week on 
a 0 to 10 scale with 0 indicating no difficulty and 10 indicating extreme 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 18 of 60  CONFIDENTIAL  
difficulty assessed at screening  and the 3- , 6-, 12-, 24- and 36-month follow -
up evaluations. 
• Sino-Nasal Outcome Test (SNOT -22) - Participant -reported outcome 
measure for the prior 2 weeks of 22 symptoms related to both nasal and 
general health on a score of 0 (no problem) to 5 (problem as bad as it can 
be) and indicate  up to 5 items they consider the most important items 
affecting their health. Scores range from 0 to 110, with higher numbers representing a significant problem for the participant.  
• Participant Satisfaction Assessment  - Five-question self -reported survey of 
satisfaction with the procedure and recommendation to others administered at the 3 -, 6-, 12-, 24- and 36- month follow -up evaluations. 
• Medications - M edication  used for relief or treatment of NAO symptoms 
will be documented at screening and updated as necessary with new 
associated medications at each postprocedure evaluation through the End of 
Study visit . An increase, decrease, no change, starting new or stoppage of 
medication use compared to the first recorded use will be documented.  
5.0 Study Plan  
5.1 Study Design 
The study is designed as a m ulticenter, prospective, open -label , single -arm study 
involving up to 10 sites in the US .  
All participants will be evaluated in -office prior to treatment and following treatment 
at week s 1 and 13 (3 months). The 3- month evaluation will be used for the primary 
endpoint analysis.  Participants will have an extended follow -up with evaluations conducted remotely at 
6 months (26 weeks), 12 months (52 weeks) 24 months (104 weeks) and 36 months 
(156 weeks).  
A subset of study sites will be selected to participate in a substudy of the use of 
computed tomography (CT) imaging to assess changes in the SBB after treatment.  
5.2 Study Population  
The target population for this study is adults suffering f rom symptoms attributed to 
NAO with evidence of  SSB obstruction of the airway which may or may not include  
hypertrophied turbinates. This study requires severe or extreme symptoms demonstrated by a NOSE S cale score ≥
 55 and determination by the investigator that 
the SSB s are the primary or significant contributor to the nasal obstruction.  
Participants who have had previous surgical treatment of the nasal valve in the past 6 months are not eligible to enroll in this study; however, it is anticipated that many participants will have already undergone rhinoplasty, septoplasty, IT reduction or other surgical procedures prior to being approached for participation in this study. Therefore, a history of those types of procedu res does not exclude a p articipant from 
enrolling in this study. However, to ensure that changes in NOSE Scale score over 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 19 of 60  CONFIDENTIAL  
the course of follow -up are the result of the Vivaer procedure, prior surgical 
procedures must have been performed at least 6 months before the participant is 
enrolled in this study and no additional procedures should take place on the day of the Vivaer procedure or in the next 3 months.  
Participants must meet all  inclusion and no exclusion criteria listed below for 
participation in the  study. 
5.2.1 Inclusion Criteria  
1. Age 22 to 85 years (inclusively). 
2. Seeking treatment for nasal  obstruction and willing  to undergo an office -
based procedure. 
3. Baseline NOSE score ≥ 55. 
4. Presence of SSB hypertrophy limiting visualization of the middle turbinate 
(MT) by more than 50%.  
5. Reduction in size of the SSB  after application  of topical decongestant on a 
cotton plug directly to the SSB  region.  
6. Improvement in the symptoms of nasal obstruction after SSB decongest ion 
suggesting that the SSB may play a role in nasal obstruction. 
7. Willing and able to withhold anticoagulant medications during the perioperative period (3 -day window on either side). 
8. Willing and able to provide informed consent.  
9. Willing and able to comply with the participant- specific requirements 
outlined in the study protocol.  
5.2.2 Exclusion Criteria  
1. Rhinoplasty, septoplasty, inferior turbinate (IT) reduction, or other surgical nasal procedures within the preceding 6 months.  
2. Severe case of any of the following: septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be the primary contributor to the participant’s nasal obstruction symptoms and warranting surgical intervention. 
3. Any adjunctive surgical nasal procedure planned on the same day or within 
3 months after the Vivaer procedure . 
4. Known or suspected allergies or contraindications for any general or local anesthetic agents.  
5. Known or suspected to be pregna nt or is lactating.  
6. Participating in another clinical research study . 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 20 of 60  CONFIDENTIAL  
7. Other medical conditions which in the opinion of the investigator would 
predispose the participant to poor wound healing or increased surgical risk, or poor compliance with the requirements of the study. 
8. Known or suspected regular use of oxymetazoline (Afrin) nasal decongestant or oral steroids is exclusionary. 
9. For sites participating in the CT  substudy only: Active sinus condition (eg, 
significant sinus diseases, infection , or polyp formation) identified by CT. 
5.3 Study Entry and Enrollment  
Participants will be considered entered into the study upon signature of the informed consent document. All participants must provide written informed consent before undergoing any study- related procedures. Participants must be diagnosed with NAO 
prior to entry into the study and it is expected that participants will have undergone standard evaluations for the diagnosis of NAO as part of their regular care. Participants will be considered enrolled in the study upon introduction of anesthetic into the nasal cavity for the purpose of the study procedure. 
5.4 Outcome Measures  
5.4.1 Nasal Assessment  
The target ed nasal  area within each nostril will be visually assessed for this 
study. The use of both visual and endoscope assessment is required. 
Observations are categorized as not present, mild, moderate, or severe. Representative endoscopic video  of each nasal passage will be captured for each 
assessment .  
General assessments include: 
• Saddle nose deformity  
• Bruising around orbital area 
• Soreness, pain 
• Numbness. 
  Endoscopic  assessments : 
• Inflammation / generalized redness  
• Swelling, edema  
• Blanching (generalized whiteness)  
• Bleeding at anesthetic injection site (not requiring physic ian 
intervention) immediately postprocedure only 
• Bleeding at treatment site (not requiring physician intervention)  
immediately postprocedure only 
• Nasal obstruction from tissue edema  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 21 of 60  CONFIDENTIAL  
• Disruption of mucosal flow / crusting  
• SSB endoscopy grading score. The SSB  endoscopy grading scale was 
developed by Catalano et al.36 to complement the more subject ive NOSE 
Scale for the purpose of evaluating the degree of reduction of the SSB  as 
seen clinically and is based on the ability to see the middle turbinate from 
the most anterior nares during endoscopy. Scores are assigned as: 
1 = visualization of >50% of the ipsilateral middle turbinate  
2 = visualization of <50% of the middle turbinate  
3 = no visualization of the middle tur binate. 
5.4.2 CT Assessment  – Substudy – Selected Sites Only  
A subset of study sites will be selected to participate in a substudy of the use of CT imaging to assess changes in the SBB after treatment.  
CT imaging will be conducted prior to the procedure and at 3 months after the procedure using the following spec ifications :  
• 120 kilovoltage peak ( KVp ) 
• Dose reduction technique according to manufacturer 
• Anatomical Scan Range: paranasal sinus 
• Slice thickness 0.4mm minimum  
• Scan Field of View (FOV) – 15cm 
• Reformat technique – Multiplanar reformation ( MPR ) 
• Contrast – none  
• Save file identified with participant ID and date of scan to DICOM 
format  
• Upload DICOM images to the designated  secure cloud content 
management system. 
SSB measurement  adapted from Gelera et al.
33 Thickness of 3 segments of the 
SSB will be measured  by an independent board c ertified radiologist :  
• the anterior part located anterior and superior to the IT , 
• the middle or widest part located anterior to middle turbinate and 
superior to IT , and 
• the posterior part located within the anterior 1/3 of the middle turbinate 
not going beyond the crista galli.  
The p osterior part of septum will be  measured at the area of h orizontal 
attachment of middle turbinate to the lateral nasal wall and superior turbinate 
to represent the less vasoactive part of the septum.  
Other structures or anatomy that may contribute to nasal airway passage 
compromise at or about  the SSB such as n asal septal deviation, turbinate 
hypertrophy/concha bullosa, polyp/cyst, will be entered into electronic Case 
Report Form (eCRF). 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 22 of 60  CONFIDENTIAL  
All CTs will be reviewed by a central reviewer.  The central reviewer is a board -
certified radiologist.  
5.4.3 Nasal Obstructio n Symptom Evaluation (NOSE) Scale  
Evaluation of NAO is based on clinical observations of signs and symptoms 
with no easily obtained, reproducible objective measurement techniques of the 
airway .3 Poor correlation and uncertainty between more objective measures of 
nasal patency  (eg, nasal inspiratory peak flow, acoustic rhinometry, 
rhinomanometry, CT scans, physician assessment of anatomy)  and 
participantive measures have generally been reported.38-42 Since participant 
symptoms and perception of condition are the factors leading an individual to seek treatment, participant- reported participantive measures are cited as the 
most important determinates of treatment outcome .
3,38,39 
To evaluate the significance of a participant’s nasal obstruction both before and 
after the procedure, this study will use the well -known p articipant-reported 
NOSE  Scale for determining the primary endpoint of the study. The NOSE 
Scale is a validated disease- specific health status instrument used by clinicians 
to measure the outcome of participants treated for nasal obstruction.43 The 
NOSE Scale consists of 5 items,  each scored using a 5 -point Likert scale to 
make a total score range of 0 through 100, where higher scores indicate worse 
obstruction. Severity of symptoms can be classified as mild (range, 5 -25), 
moderate (range, 30- 50), severe (range, 55- 75), or extreme  (range, 80-100) 
nasal obstruction, based on responses to the NOSE Scale survey.44 
Treatment responder based on NOSE Scale score improvement: 
A responder is defined as 1 NOSE Scale class improvement (eg , going from a 
score in the severe range (55 -75) at preprocedure to a score in the moderate 
range (30 -50) at the 3 -month evaluation), or an improvement (decrease) in 
NOSE Scale score of 20% or more from screening at the 3 -month evaluation. 
5.4.4 Visual Analog Scale (VAS) for Nasal Pain   
A horizontal 100 mm  VAS45 anchored on the left with the words “No Pain” and 
on the right with the words “Worst Pain Imaginable”, will be used to measure nasal pain associated with the procedure. Scores are obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a vertical slash placed by the participant to indicate their current level of pain in and around the nose. 
5.4.5 Ease of Breathing  Through the Nose  – Numeric Rating  Scale (NRS) 
Breathing Score  
Participants will be asked to describe their perception of their ability to breathe 
through the nose over the past week on a NRS from 0 to 10 where 0 is defined as “No Difficulty Breathing” and 10 is defined as “Extreme Difficulty Breathing”.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 23 of 60  CONFIDENTIAL  
5.4.6 Sino -Nasal Outcomes Test 22 (SNOT -22) 
The SNOT -22 is a disease- specific, 22 -item, participant -reported outcome 
measure of the prior 2 weeks of symptoms originally developed and validated 
specifically for rhinosinusitis46 that has also been described and used in the 
context of NAO.47,48 participants rate 22 different symptoms related to both 
nasal and general health on a 6- point Likert scale of no problem (0), very mild 
problem (1), mild or slight problem (2), moderate pro blem (3), severe problem 
(4), and problem as bad as it can be (5) and indicate up to 5 items they consider the most important items affecting their health. Scores on the SNOT -22 are 
scaled from 0 to110, with higher numbers representing a significant proble m to 
a participant ’s life. Individual studies have consistently shown that SNOT -22 
scores improve after endoscopic sinus surgery in adults with chronic rhinosinusitis with the minimal clinically important difference commonly considered to be a change of 8.9 points; however, the magnitude of changes across studies is quite variable.
49 
The SNOT -22 has also been shown to measure 5 underlying domains, each of 
which may be impacted differently depending on the therapy or intervention involved.
50. The domains are  3 sinus -specific symptom domains (Rhinologic, 
Extra -nasal rhinologic and Ear/Facial symptoms) and 2 general health -related 
QOL domains (Psychological and Sleep dysfunction). The domains are defined by grouping individual items from the 22 total items: 
• Rhinologic symptoms - Items 1, 2, 3, 6, 21, 22 (0-30 score) 
• Extra -nasal rhinologic symptoms - Items 4, 5, 6 (0- 15 score)  
• Ear/Facial symptoms - Items 2, 7, 8, 9, 10 (0- 25 score)  
• Psychological dysfunction - Items 14, 15, 16, 17, 18, 19, 20 (0-35 score) 
• Sleep dysfunction - Items 11, 12, 13, 14, 15 (score 0-25). 
Reporting individual domain scores may help improve the sensitivity and usefulness of the SNOT -22 for the specific procedure in this study.  
5.4.7 Participant Satisfaction Assessment  
Five-question self-reported survey of satisfaction using a 5- point scale to assess 
tolerability of the procedure, ease of recovery, change in breathing through nose, overall satisfaction with the procedure, and recommendation to others. 
5.4.8 Medication s for Symptoms of Nasal Obstruction  
Medication  used for relief or treatment of NAO symptoms will be documented 
at screening  and updated as necessary with new associated medications at each 
postprocedure evaluation through the End of Study visit . An increase, decrease, 
no change, starting new or stoppage of medication use compared to the first recorded use will be documented.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 24 of 60  CONFIDENTIAL  
5.4.9 Adverse Events  
Adverse events will be documented according to Section 8.1. 
5.5 Success/ Failure Criteria  
Determinations of the overall success of treatment will be based on 2 levels: (1) the 
individual p articipant level and (2) the overall treatment success. Each level has its 
own criteria for success.  
5.5.1 Participant Success  
The primary outcome success measure for a participant  in this study is based 
on an improvement (decrease) in the NOSE Scale score after the procedure compared to the baseline ( screening ) score. The improvement must reflect  at 
least one category improvement or ≥
 20% decrease in score at the 3 -month 
evaluation for the participant  to be considered a success (responder).  A 
participant  will be considered a nonresponder (failure) at the 3 -month 
evaluation if neither success criterion has been attained.  
5.5.2 Study Succ ess 
The study will be considered a success if the mean improvement in NOSE Scale score from baseline ( screening ) to 13 weeks exceed s 25 points.  
5.6 Duration of the Study  
The primary endpoint will be evaluated at 3 months . In addition, evaluations at 6 , 12, 
24 and 36 months after treatment will extend follow -up to 3 years for evaluation of 
longer- term efficacy. Study e nrollment is anticipated to be completed within 6 
months. Therefore, total study duration is anticipated to be approximat ely 42 months. 
5.7 Site Staffing and Responsibilities of Study Personnel  
The principal investigator is responsible for ensuring that they have  sufficient and 
qualified staff to conduct the clinical study and that all study- related tasks have been 
appropriately delegated and documented. Roles may include : 
• Investigator/Treating  Physician - The Investigator/T reatin g Physician  will 
perform the procedure and postprocedure assessments. The treating physician  
must be a medical doctor with experience in ENT procedures and trained on 
study procedures, including the administration of the Vivaer  procedure for 
treatment of SSB . 
• Oversight of participant -reported outcomes and other data collection – 
Medical or office staff with relevant knowledge and experience as determined by the principal investigator to interact with study participants to ensure collection of study data and participant- reported outcome s. 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 25 of 60  CONFIDENTIAL  
5.8 Risk/Benefit Analysis  
5.8.1 Risks  
Potential risks associated with the use of the Vivaer ARC Stylus do not differ 
from commonly used devices and treatments for nasal obstruction and snoring, but due to the nonsurgical nature of the therapy, small treatment area, low energy delivery, and lack of need for general anesthesia, the overall risk to the participant may be less than presented by other surgical treatments such as RF turbinoplasty, septoplasty, or functional rhinoplasty. 
Potential risks associated with the use of the Vivaer ARC Stylus  and the 
associated local anesthetics are listed below. participants will be monitored 
closely as part of this study to allow for early detection of potential problems and prompt treatment if required.  
Anticipated adverse events or side effects that may occur as a result of the 
treatment include :  
• Infection  
• Bleeding (other than during the treatment at treatment sites and greater 
than anticipated by the investigator)  
• Mucosal changes  
• Scar formation leading to nasal obstruction  
• External deformity  
• Sensory changes at treatment site   
• Bruising including around the orbital area (black eyes) 
Anticipated observations that are expected in and around the treatment area and 
are considered minor include: 
• Inflammation / generalized redness  
• Temporary swelling, edema  
• Blanching (generalized whiteness)  
• Temporary numbness/tingling  
• Temporary soreness/pain 
• Mild bleeding at anesthetic injection and/or treatment site (not requiring physician-level intervention, such as cautery) 
• Temporary nasal obstruction from tissue edema  
• Disruption of mucosal flow/intranasal crusting  
• Scab formation 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 26 of 60  CONFIDENTIAL  
These observations will be assessed in the nasal assessment and recorded at 
study visits if they occur. Should any of the events above  require mitigation by 
the treating physician or be greater in severity or degree of incidence than anticipated, they will be considered an adverse event and will be recorded on the study Adverse Event Report electronic case report forms (eCRF) . 
Symptomatic improvements may not be achieved in all participants receiving the Vivaer procedure and may not be durable beyond the 3 -month evaluation in 
all participants who achieved relief at 3 months.  
5.8.2 Potential Risks to Participant Confidentiality  
In all clinical studies, confidentiality of protected health information may be breached due to study- related activities beyond those of routine clinical care. 
This risk will be minimized by not entering personally identifying information into the EDC system through the study’s eCRF. Risks to participant confidentiality are further minimized by allowing only authorized individuals to access the EDC system and the database that stores the electronically entered data. The 21 CRF Part 11 compliant and validated system maintains audi t trails 
on all entries, changes or corrections to eCRFs. If a person with authority to complete but not sign eCRFs makes changes to an already signed eCRF, the investigator will be required to resign the eCRF, thereby protecting the integrity of the data collection process and the data.  
5.8.3 Mitigation of Risks  
The study was developed based on previous preclinical and clinical experience and includes a number of steps to minimize any additional risks to participants in the study: 
• Preclinical mechanical and bench evaluations have been conducted to demonstrate that  the design characteristics of the study device are 
appropriate for reliable clinical use of the device.  
• The Vivaer ARC Stylus  and Console have been cleared for use by the 
FDA based in part on prior clinical studies demonstrating safety and efficacy of their use and are CE -marked in the European Union. 
• The study will be reviewed and approved by an Institutional Review 
Board(s) and conducted according to applicable regulations with 
ongoing review by the IRB. 
• Careful consideration has been given to the inclus ion/exclusion criteria 
in order to select appropriate candidates for treatment.  
• Participants  will be fully informed of the study requirements prior to 
enrollment.  
• Only physicians with experience in nasal surgical and minimally 
invasive procedures, and with  specific training using the Vivaer ARC 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 27 of 60  CONFIDENTIAL  
Stylus for performing the Vivaer  procedure will be permitted  to 
participate in the study. 
• Study procedures, f ollow -up, and study monitoring are  designed to 
identify and closely manage adverse events in a timely manner.  
5.8.4 Study Justification in Relation to Risk  
The sponsor believes that any additional risks presented by participating in this 
study are very low and that adequate testing, safeguards, and risk monitoring 
have been incorporated into the study to further minimize and mitigate the risks relative to the potential benefits, including relief from symptoms of nasal obstruction, that may be realized by participation in this study. 
5.8.5 Benefits  
The potential benefit associ ated with the Vivaer procedure is to offer a 
minimally invasive treatment method that has been shown in a previous study to help alleviate symptoms of nasal obstruction and which has been cleared for use by the FDA and is CE -marked in the European Union. T he Vivaer ARC 
Stylus improves nasal breathing by modifying the tissues of the nasal airway using low doses of RF energy. The low -power RF energy generates heat within 
the tissue and creates a coagulation lesion. As the lesion heals, the tissue retracts and stiffens, thereby decreasing NAO and improving airflow. In addition to 
symptom relief after correcting nasal obstruction, participants may also experience better sleep function and better psychological function. (eg, concentration, productivity, and frustration). These benefits may last beyond the length of the study. 
6.0 Study Schedule and Procedures  
This section provides summaries of the study Schedule of Events and flow of participants through the study, as well as more detailed information on study procedures and processes.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 28 of 60  CONFIDENTIAL  
6.1 Schedule of Events  
 
 
 
Activity / Assessment  
Screening  Treatment Follow -up  
(in-office) Extended Follow -up 
(remote) Preprocedure  
Procedure  
Immediate 
Postprocedur e 
1 Week  
3 Months  
(13 weeks)  
6 Months  
(26 weeks) 
12 Months  
(52 weeks)  
24 Months  
(104 weeks)  
36 months  
(156 weeks)  
 Window (days)  (-30) (0) (± 3) (± 14) (± 30) (± 30) (± 30) (± 30) 
Eligibility  X          
Consent  X          
Demographics / Medical History X          
Physician Evaluations            
Nasal Assessment ( visual , 
endoscopic) X X1  X X X     
CT imaging of SSB X2     X     
Current m edication use (study 
relevant)  X   X3 X X X X X X 
Participant Evaluations   
NOSE Scale  X4     X5 X X X X 
VAS nasal pain     X X      
NRS  ease of breathing  X     X X X X X 
Participant Satisfaction Survey       X X X X X 
SNOT -22 X     X X X X X 
Study Procedure (includes 
anethesia)    X        
Adverse Events  X   X X X X X X X 
 
1 Nasal Assessment do not need to be repeated if Screening and Treatment visits occur on the same day . 
2CT should only be performed  if your site was selected for the CT substudy and  only after all other screening procedures and 
participant eligibility is co nfirmed.  
3Add any postprocedure medications to the medication log . 
4Baseline NOSE Scale Score for analysis is defined as the Screening score.  
5Primary analysis endpoint  evaluation.  
 
 
       
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 29 of 60  CONFIDENTIAL  
6.2 Participant Flowchart  
 
 
6.3 Enrollment and Screening  Assessment  
Screening  
During screening , the investigator or designated research staff will perform a n 
evaluation of the study candidate for study eligibility, which will include a history 
and physical examination of the nasal area  bilaterally , review of overall medical 
history, history of allergies,  understanding of general health and discussion of any 
conservative measures used for NAO.  
Participants must be diagnosed with NAO prior to entry into the study. While the 
availability of the study may be discussed with a prospective  participant without first 
obtaining consent, informed consent must be obtained prior to initiation of any clinical procedures dictated by the protocol that are performed solely for the purpose 
Consented Participants  
Vivaer  procedure 
1-week follow-up 
Primary Endpoint 
Extended follow -up 
6 months 
 
12 months 
 
24 months 
 
36 months 
13-week follow-up 
Enrolled 
Participant 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 30 of 60  CONFIDENTIAL  
of determining eligibility to participate in the study. A part icipant will be considered 
as being entered into the study once informed consent is provided. Once the 
participant is entered into the study, screening assessments are completed , and the 
study treatment (preprocedure, procedure and immediate post procedure) should be completed within 30 days .  
Informed Consent 
Informed consent must be obtained in accordance with FDA regulation 21 CFR Part 50 and ISO 14155. The investigator or designated staff member is responsible for 
ensuring that IRB current and approved informed consent is obtained for each participant prior to participation in the study, or before undergoing any procedure specific to the clinical investigation. The participant must be fully counseled with an explanation of the study background, non- rando mized nature of the study, study 
procedure, follow -up schedule, and informed of their options, risks and benefits, and 
have every opportunity to ask questions about participation in the study. Any new information obtained during the course of the study tha t may affect the health of the 
participant or their decision to continue in the study will be provided to the participant. This process includes a thorough explanation of the informed consent document that the participant will be asked to sign and date ack nowledging that they 
understand and desire to participate in the study. The explanation and discussion should be conducted in such a way as to: 
• answer the p articipant’s questions,  
• avoid coercion or influence of participant to participate in the study,  
• ensure the p articipant understands that their legal rights are not waived at any 
time,  
• use language at a level the participant can understand, and  
• ensure the participant understands that after providing signature on the informed consent, the participant may still withdraw at any time before, 
during or after study treatment.  
A copy of the signed informed consent document should be provided to the participant.  
Evaluation of Inclusion and Exclusion C riteria  
The Screening Visit / Study Eligibility eCRF will be used to document the participant’s eligibility status.   
Screening  Data and A ssessments  
The following data will be obtained at Screening and recorded on the Screening  Visit 
– Demographics, Treatment History and Nasal Exam e CRF : 
• Demographics 
o Sex 
o Height (inches)  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 31 of 60  CONFIDENTIAL  
o Weight (pounds) 
o BMI  
o Date of birth  
o Race / Ethnicity  
• Medical history, Nasal Symptoms, History of Treatments, General Nasal 
Exam  
o History (duration) of nasal obstruction 
o History of nasal trauma  
o Related nasal symptoms  
o History of  rhinitis  (allergic, non allergic ), sinus disease, and/or 
obstructive sleep apnea  
o participant -reported, Medication/treatments used to address nasal 
obstruction and/or related symptoms , including continuous positive 
airway pressure ( CPAP)  
o Evaluation of s ignificant anatomic conditions that could affect 
treatment outcome  (eg, severe septal deviation, turbinate enlargement, 
nasal polyps, ptotic nasal tip, and/or other external nasal deformity ) 
• Nasal assessment ( visual and endoscopic exam ) for each nostril including 
representative video of each nasal.  
• (Selected  sites only) CT to assess changes in the SSB  after treatment will be 
collected at a  subset of study sites. 
• Current use of medication for symptoms of nasal obstruction will be 
detailed on the Nasal Medication Log  
• Current use of devices, or other therapies. 
• Screening NOSE Scale score (completed by participant).   
• NRS ease of breathing score (completed by participant).  
• SNOT -22 (completed by participant).  
• Adverse Events.  
6.4 Treatment Visit and Procedure (Day 0) 
The treatment is summarized below  and is comprised of the p reprocedure, procedure 
and postprocedure  as indicated on the Schedule of Events ( Section 6.1 ). The 
treatment visit should occur within 30 days of the Screening Visit (study entry), once 
all inclusion and exclusion criteria have been met.  Consult the Aerin Console 
Instructions for Use  (IFU) for full detail of the standard treatment procedure  and step-
by-step instructions for preparation and use of the Vivaer ARC Stylus  and Aerin 
Console. 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 32 of 60  CONFIDENTIAL  
Preparation  (preprocedure)  
The treatment will be performed in the study clinic within 30 days of study entry. 
The participant will be seated and positioned in the exam chair according to personal 
comfort and study physician’s preference (eg, upright, reclined or supine). A nasal assessment ( visual and endoscopic exam) will be performed on each side of the nose 
and for each nostril, including endoscopic video. This is to assess the configuration of the structural components of the lateral nasal wall (including the upper and lower lateral cartilage, their junction and the overlying mucosa), location of SSB and the MT to allow the study physician to map out and plan the areas of treatment. If the 
Screening and Treatment visits occur on the same day, the nasal assessme nt does not 
need to be repeated for P reprocedure.  
Following the nasal assessment, it is recommended t he study physician prepare the 
treatment area with a topical anesthetic agent (eg, lidocaine, t etracaine, etc .) and 
applying via spray, gel, or saturated pledget placed within the nose. After an 
appropriate amount of time, the SSB is then visualized with an endoscope and 
infiltrated in a submucosal plane with a small amount of local anesthetic to provide adequate tissue analgesia as well as tumescence to fac ilitate radiofrequency energy 
transfer. For example, cottonoid pledgets saturated with 4% lidocaine are placed in 
the nasal passages adjacent to the septum; after 5 minutes, these pledgets are removed and the swell body is injected bilaterally with 0.4 cc of 1% lidocaine with 1:100,000 
epinephrine on each side.  
Treatment a dministration  
Once the nasal cavities have been anesthetized , participants will undergo bilateral 
treatment of the SSB in a single study procedure session. Each side of the nose will be treated as follows  
• A nasal speculum is inserted into the nostril and opened to visualize the treatment area. The Vivaer ARC Stylus  will then be inserted to access the 
treatment area. The Stylus will be connected to the Aerin Console generator and the RF en ergy level will be set on the generator. 
• Two (2) to  six (6) nonoverlapping applications of RF energy are performed at 
the SSB per nostril.  
• For the SSB, Vivaer ARC stylus default settings will be employed. ( Figure 4).  
 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 33 of 60  CONFIDENTIAL  
 
Figure 4.  Vivaer ARC Stylus  applied at SSB  
 
The default settings for the Vivaer ARC Stylus : 
Temperature   60° C 
Power    4 Watts  
Treatment Time  18 secs  
Cooling Time  12 secs  
The Aerin Console is activated by depressing the foot pedal. With the Vivaer ARC 
Stylus pressed against the tissues in the desired treatment locations, the foot pedal is 
depressed , and the Stylus is gently pressed against the nasal tissues to deliver RF 
energy to the tissues consistent with the IFU. A tone sounds when the Console is 
activated, signifying that energy is being delivered through the Stylus . The tone stops 
when the pedal is released , and RF energy is no longer being delivered.  
No repeat ("touch- up") procedures will be permitted during the study follow-up 
period. Additionally, for the purposes of this study, no other  concomitant treatments 
are permitted during this treatment or the follow -up period. 
Procedure data collection  
Data  relating to the procedure and the products used will be recorded on the Study 
Procedure e CRF . The following information  will be recorded:  
• Date of procedure. 
• Procedure and postprocedure medications ( including anesthesia).  
• Aerin Console serial number. 
• Procedure start and end times.  
• Aerin Console settings.  
• Treatment duration  and number  of sites treated for SSB . 
• Occurrence of device malfunctions, protocol deviations, and/or adverse events.  

  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 34 of 60  CONFIDENTIAL  
6.5 Postprocedure Assessments and Care  
Immediately postprocedure, a nasal assessment ( visual and endoscopic exam ) for 
each nostril including endoscopic video will be conducted prior to discharging the 
participant and reported on the Study Procedure eCRF.   
Participants will be asked to indicate the pain level experienced during the study 
procedure from anesthesia delivery to procedure completion using the VAS pain 
score instrument on the Pain VAS CRF.  
At the discretion of the study physician, the following care may be provided and 
should be documented: 
• Use of nasal saline spray and antibiotic ointment 2 to 3 times daily for 1 week . 
• The participant should be instructed not to manipulate the treatment site ( i.e., 
no nose blowing) for 24 hours with the exception of any necessary hemostasis.  
• Remind participant to continue to hold all anticoagulants for 3 days post 
procedure. 
Participants should have their first study follow -up visit (1 week +/ - 3 days) 
scheduled within the visit window prior to release. 
Participants should not receive other concomitant nasal treatment therapies (other 
than those specified above) or interventions after the procedure through the 36-month 
follow -up to avoid confounding the evaluation of the effect of the treatment, unless 
the additional care is in response to an adverse event or is considered in the best interest of the participant. Should a treatment or procedure be in the best interest of 
the participant, it must be documented in the source.  The participant will remain in 
the study and be followed through 36 months. Concomitant nasal treatments will be monitored at follow -up evaluations.   
6.6 Follow- up Evaluations  and Study Exit  
Follow- up visit dates wil l be calculated from the study procedure date (Day 0). 
Follow- up visits should be scheduled within the specified visit windows described in 
the Schedule of Events (Section 6.1) and Table 1 (Section 9.3.2). An in- office follow -
up evaluation is scheduled for  1 week and 13 weeks (3 months) after the procedure. 
In addition, follow -up evaluations at 26 weeks (6 months), 52 weeks (12 months), 
104 weeks (24 months) and 156 weeks (36 months) after the treatment procedure will be conducted remotely as a telephone assessment by site personnel. The timing of all follow -up evaluations is based on the date of the procedure and should not be altered 
based on the actual time of preceding follow -up visits. Participants who make non-
study visits should be evaluated for possi ble adverse events and an Adverse Event 
Report eCRF should be submitted if appropriate.  
All participants should be followed through the final follow -up evaluation at 156 
weeks (36 months) postprocedure regardless of their earlier success/failure classification. Every effort should be made to avoid having participants withdraw 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 35 of 60  CONFIDENTIAL  
from the study (Section 10.6). If a participant does choose to withdraw from the 
study, it is very important to record information regarding the reason(s) and the last 
known status of the participant.  
The following assessments will be conducted as indicated for each follow -up time 
points and recorded on the Follow- up V isit e CRF:  
In-office evaluation  - 1 Week:  
• Nasal assessment ( visual and endoscopic exam) for each nostril including 
endoscopic video. 
• Current use and any change in use of medication . 
• VAS for pain score (completed by participant).  
• Adverse events. 
In-office evaluation  - 3-month (13 Week s): 
• Nasal assessment (visual and endoscopic exam) for each nostril including 
endoscopic video. 
• Review of current use and change in use of medication for symptoms of nasal 
obstructions. 
• NOSE Scale score (completed by p articipant).  
• NRS ease of breathing score (completed by participant).  
• SNOT -22 (completed by participant).  
• CT imaging  (Substudy – s elected sites only ). 
• Participant Satisfaction Survey (completed by participant).  
• Adverse events. 
Remote  evaluations - 6- month (26 Weeks), 12-month (52- Week s), 24-month (104-
Weeks) and 36- month (156- Weeks) follow-up: 
• Current use and participant -reported change in use of medication, and other 
therapies for symptoms of nasal obstruction and p articipant -reported changes 
in frequency of use. 
• NOSE  Scale score (verbal administration by site personnel). 
• NRS ease of breathing score (verbal administration by site personnel). 
• SNOT -22 (verbal administration by site personnel). 
• Participant Satisfaction Survey (verbal administration by site personnel).  
• Adverse events (study staff follow -up required if participant indicates an 
event). 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 36 of 60  CONFIDENTIAL  
Study exit: 
Participants meeting the study requirements as planned will be exited from the study 
upon completion of the 36- month follow -up evaluation. If a participant reach es the 
36-month follow -up evaluation and is experiencing a new or ongoing adverse event, 
the study sponsor should be contacted to discuss the need and/or methods for continued surveillance of the event. 
Study exit applies to those participants where data i s no longer collected for a study 
participant. A Study Exit f orm should be completed and entered into the e lectronic 
data c apture ( EDC) System s in the following cases:  
• Completion of 36 month participant questionnaires 
• Signed consent but no procedure took place  (eg, screen failure)  
• Participant was unable to complete the follow-up visits 
• Withdrawal of informed consent  
• Physician exited p articipant based on medical or surgical necessity or 
other reason   
• Participant received treatment outside of the study that, in the opinion 
of the investigator, would affect the study results.  
• Lost to follow -up (3 attempts should be made and documented in the 
participant’s record  indicating due diligence by the site) 
o If a participant misses a questionn aire window and cannot be 
contacted, the participant may remain in the study, as contact may be re-established  for a future questionnaire wi ndow period. (Any missed 
study assessment is considered a protocol deviation.) Participant  
withdrawal should be repor ted within 5 days of site becoming aware. 
participant  death should be reported within 24 hours to Aerin Medical.  
• Participant Death  
6.7 Product Handling and Accountability  
A system that allows tracking of orders, shipping and returns will be used to control 
the Vivaer ARC Stylus  inventory. The devices  will be packaged and labeled to clearly 
indicate that they are for clinical study  use only and must only be used for particip ants 
enrolled in this study. All devices  not used must be returned to the sponsor disposed 
of in accordance with the sponsor’s instructions. The investigator is responsible for 
adequate record keeping regarding the receipt, use, and final disposition  of st udy 
inventory. 
7.0 Statistical Considerations  
7.1 Study Design 
This is a prospective, m ulticenter, open -label, single -arm study to assess the Vivaer 
procedure for treatment of SSB to improve symptoms in those diagnosed with NAO.  
This study is designed to assess improvement in symptoms from prior to the 
procedure to a primary endpoint at 3 months after the procedure and out to 36 months. 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 37 of 60  CONFIDENTIAL  
7.2 Study Hypotheses  
The primary endpoint hypothesis for the primary study objective is designed to 
demonstrate that the mean improvement in participant NOSE Scale score from the baseline assessment  at screening  to 13 weeks exceeds 25 points. Note that 
improvement is represented by a decrease in NOSE score. The null hypothesis (H
0) 
is that the decrease in mean NOSE Scale score will be less than 25 points and the alternative hypotheses (H
1) is that the decrease will be more than 25 points:  
H0: µd ≥ −25.0 
H1: µd < −25.0,  
where µ d represents the mean change in NOSE Scale score from baseline to 13 weeks  
(13-week  NOSE Scale score −  baseline NOSE Scale score ). Rejection of the null 
hypothesis in favor of the alternative hypothesis  (H1) means that there is evidence for 
a statistically significant reduction in mean NOSE Scale score from baseline to 13 
weeks postprocedure. 
The secondary endpoint hypothesis for the primary study objective is designed to 
show that the proportion (percent) of participants meeting  the responder definition 
will exceed 0.55 (55%) at 13 weeks. The null hypothesis (H 0) is that the proportion 
of responders will be equal to .55 (55%) and the alternative hypotheses (H 1) is that 
the proportion of responders will exceed 0.55 (55%): 
H0: p0 = 0.55  
H1: p > 0.55,  
where p0 represents the targeted minimum responder proportion at 13 weeks and p 
represents the expected proportion at 13 weeks.  
7.3 Power Analysis and Sample Size Estimate  
The study will enroll up to 70 participants. The power analysis was performed such that there is adequate power to reject the null hypothesis for both the primary effectiveness endpoint and for the principal secondary endpoint. 
The statistical power (1 – β) for the primary effectiveness endpoint that , on avera ge, 
there is  at least a 25-point improvement in the NOSE Scale score from the 
pretreatment  assessment to the assessment at 13 weeks:  
Statistical Hypothesis:  H 0: µd > -25.0 versus H 1: µd < -25.0 
where µ d is the average change from screening (baseline) 
in the NOSE Scale score at 13 weeks post treatment  
Statistical Methodology:  Single- sample paired t -test 
Expected µ d: -50 
Standard Deviation: 20 Significance Level:  One-sided α = .025 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 38 of 60  CONFIDENTIAL  
Minimum Sample Size:  70 Participants  
Statistical Power:  0.99 
The statistical power (1 – β) for the secondary endpoint is such that at least 55% of 
the treated participants respond to treatment, defined as either at least one NOSE 
Scale class improvement, or at least a 20% improvement in the NOSE Scale score, 
both assessed  at 13 weeks posttreatment : 
Statistical Hypothesis:  H 0: π < 0.55 versus H 1: π > 0.55 
where π is the proportion of participants responding to 
treatment 13 weeks posttreatment  
Statistical Methodology:  Single- sample chi-square test  
Expected π: 0.80 
Significance Level:  One-sided α = .025 
Minimum Sample Size:  70 Participants  
Statistical Power:  0.99 
With at least 70 treated participants, we can be 95% confident that we will observe 
at least one unexpected serious device- related event when the underlying incidence 
of that event is at least 2.3%.  
It is anticipated that participants will be enrolled at sites on a competitive basis; 
however, a reasonable balance of participants among sites may be maintained by potentially capping enrollment at indi vidual sites based on the final number of 
participating sites.  
7.4 Timing of Analysis  
The primary evaluation phase of the study lasts until all participants have reached the primary endpoint at 13 -weeks (3 -month) postprocedure. The primary and secondary 
endpoints will be analyzed using the data from the primary evaluation phase for an 
interim study report when these data become available. Informational outcomes will be analyzed and may be included in interim reports after all participants have reached each of the successive follow -up time points. A final study report will be provided 
after all participants have reached the final 36 -month follow -up evaluation of the 
extended follow -up phase of the study. 
7.5 Analysis Populations  
All enrolled  participants entered in the study will comprise the safety population and 
will be subject  to all safety analyses. All  enrolled participants undergoing the 
procedure ( initiation of an esthesia ) represent the evaluable study population. For 
some evaluations, summaries will be presented by nostril. The per -protocol 
population is defined as all p articipants who received treatment, with 13 -week (3 -
month) follow -up data and no major protocol deviations.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 39 of 60  CONFIDENTIAL  
7.6 Missing Data  
Every effort will be made to obtain complete follow -up data for all participants, and 
it is anticipated that analysis of the primary and secondary endpoint hypotheses will 
be conducted using all available complete data. The effect of mi ssing data will be 
examined by imputing missing NOSE scores as no change from baseline and as nonresponders.  
Other  outcome measures will be analyzed by using available data only. 
7.7 Pooling  
All study data will be pooled across study sites to facilitate h ypothesis testing in 
accordance with the sample size estimation and power analysis (Section 7.3). 
Comparability between study sites may be shown using summary statistics calculated 
by site.  
7.8 Participant Disposition  
A detailed description of participant disposition will be provided using a CONSORT 
diagram and summaries of participants falling in various subgroups of interest, such as, consented but not treated, discontinued, major protocol deviations, deaths, and withdrawals. All study population exclusions and reasons will be summarized. All participants entered in the study will be accounted for in the summary. Follow -up by 
visit will be presented, showing theoretical, expected, and actual follow-up visits. 
7.9 Demographics and Baseline Characteristics  
Demographics and  baseline characteristics will be summarized using frequencies and 
percentages for categorical factors and mean, median, SD , minimum and maximum 
for continuous factors.  
7.10 Primary Endpoint  Analysis 
The primary endpoint hypothesis of change from baseline to the 13- week endpoint 
will be  analyzed using a paired t- test at the 1-sided alpha .025 level and presented as 
the mean change with associated 1-sided lower confidence bound. 
7.11 Secondary Endpoint  Analysis 
The s econdary endpoint hypothesis will be tested only after the primary endpoint of 
the study is met.  The secondary hypothesis  will be evaluated using the proportion of 
responders on the primary outcome measure  at 13 weeks. A responder is  defined as 
having improvement in NOSE Scale score of ≥ 20% from  baseline or at least one  
NOSE Scale class improvement.  
The hypothesis will  be tested at the 1- sided alpha .025 level with a single proportion 
binomial test. The responder proportion (percent) will be presented with the 
associated  95% confidence interval.  The secondary endpoint will be met if the lower 
bound of the confidence interval exceeds 0.55 (55%). 
The frequency (p roportion) of septal perforation  will be calculated along with the 
95% confidence interval along with a summary of each event. 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 40 of 60  CONFIDENTIAL  
The frequency ( proportions) of serious device -related adverse events and procedure -
related adverse events will be calculated alon g with the 95% confidence interval 
along with a summary of each serious event. 
7.12 Othe r Outcome Measures Analyses 
Additional outcome measures will be  collected for information and  hypothesis 
generating purposes. The primary analysis methods will be descriptive and 
exploratory and presented by evaluation to more completely understand the time 
course of treatment effect . Measures will be summarized using frequencies and 
percentages f or categorical measures and mean, median, SD, minimum and 
maximum for continuous factors.  Statistical comparisons will either not be performed 
or used for information purposes. Proportions may be compared using exact tests , 
chi-square tests, or general linear models . Continuous outcomes may be compared 
using t -tests or nonparametric equivalents. Repeated measures linear mixed models  
may be used for longitudinal analysis across evaluations.  
Other  outcome measures include: 
• Nasal Assessment  - The visual and endoscopic assessment factors will be 
summarized to include frequency and percentage of responses in each category for each component of the nasal assessment by treatment group at screening , just prior to procedure (if screening and procedur e occur on 
different days), immediately after procedure and at 3 months . The 
distribution of SSB  grades prior to the procedure and at each follow -up will 
be summarized along with the mean scores and change from screening . 
• Radiographic Imaging  - A subset of  study sites will be selected to 
participate in a substudy of the use of CT  imaging to assess changes in the 
SBB after treatment. SSB  measures from CT scans will be summarized and 
presented as means at screening and at 3 months and as the mean change 
from screening to 3 months.  
• NOSE Scale score  - Categorical responses and scores on the NOSE Scale 
and its individual components will be subject  to multiple summary methods 
and analyses including the:  
o Mean  and mean change from preprocedure at the 3 -, 6-, 12- , 24- and 
36-month follow -up evaluations. 
o Distribution of NOSE Scale score severity categories (mild, moderate, severe, extreme) at the 3 -, 6-, 12-, 24- and 36-month 
follow -up evaluations for each group. 
o Mean, change from preprocedure in mean, and response distribution 
of the 5 components of the NOSE Scale score (nasal congestion, nasal blockage, trouble breathing, trouble sleeping, and getting enough air during exercise) at the 3- , 6-, 12 24- and 36-month 
follow -up evaluations for each group. 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 41 of 60  CONFIDENTIAL  
o Proportion of responders based on improvement in NOSE Scale 
score at the 3 -, 6-, 12-, 24- and 36- month follow -up evaluations for 
each group. 
• VAS for nasal pain- Summary will include mean NRS pain scores assessed 
postprocedure. 
• NRS  for ease of breathing  - Summary will include mean and mean change 
from baseline (screening ) of ease of breathing scores assessed at s creening  
and at each follow-up evaluation. 
• SNOT -22 - mean and change from baseline (screening) in mean SNOT -22 
score and individual domain score s will be summarized at the 3 -, 6-, 12- , 
24- and 36- month follow -up evaluations. 
• Participant Satisfaction Assessment  - mean response for each of the 5 
survey questions will be summarized at the 3- , 6-, 12- , 24- and 36- month 
follow -up evaluations. 
• Medicatio ns - Medication,  and other therapies  associated with relief or 
treatment of NAO symptoms will be documented at screening  and updated 
as necessary with changes to any treatment and any new associated 
medications at each postprocedure evaluation. An increase or decrease in 
frequency of use or dose, no change, starting new or stoppage of medication 
use compared to the first recorded use will be documented.  
7.13 Subgroup Analysis  
A subgroup analysis of primary and secondary efficacy meas ures based on allergic 
or nonallergic classification will be performed  for the 3- month endpoint using a 2-
sample t -test to compare changes in mean NOSE Scale score between the 2 groups 
and a 2 sample binomial or exact test to compare the responder percents between the 
2 groups.  
Other exploratory subgroup analyses may be performed based on demographic, 
procedural, or other identified characteristics. Potential baseline covariates with 
possible impact on outcomes at 3 months are: 
• Age  
• Race 
• Sex 
• BMI  
7.14 Safety Analysis 
All adverse events, collected from the time of study consent (study entry) until the end of the study will be analyzed for all participants . Adverse events may occur 
during the treatment phase or during the follow -up phase. AEs occurring af ter the 
screening assessment but before the procedure (application of anesthesia) will be 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 42 of 60  CONFIDENTIAL  
documented in the participant’s medical record and EDC but will not count as related 
to the study device or procedure. Adverse events will be coded using a custom Aer in 
Medical dictionary so that adverse events may be categorized for analysis at an appropriate level of detail. Listings will be provided to detail individual events. The number of p articipants, number of AEs, and the proportion of participants reporting 
each AE will be summarized. Seriousness and severity of AEs and their relationship 
to the device and procedure will be summarized. A time course of adverse events will be presented. Any unexpected adverse device experiences or adverse events that occur at a n unexpectedly high incidence rate will receive detailed analyses. 
Narratives will be presented for all deaths, serious adverse events, unexpected adverse device experiences, and participants withdrawn due to an adverse event. 
7.15 Follow- up Phase Analysis  
The follow -up phase analyse s will be similar to th ose detailed above with a particular 
emphasis on the summarization of all adverse events occurring throughout the entire 
study and the maintenance of the treatment effect over time.  Missing data analyses 
and imputation will not be performed on data collected during the extension phase. 
7.16 Standard Methods of Report  
Summary descriptive statistics including means, medians, standard deviations and histograms for continuous measures, and frequencies and percentages for categorical outcomes will be presented for all variables of interest. Outcome measures (primary , 
secondary , and informational ) will be presented by evaluation. 
8.0 Adverse Events and Product Complaints / Device Deficiencies  
8.1 Adverse Events  
All adverse events, collected from the time of study consent (study entry) until the end of the study will be analyzed for all participants . Adverse events may occur 
during the treatment phase or during the follow -up phase. AEs occurring after the 
screening assessment but before the preprocedure (application of anesthesia) will be 
documented in the participant’s medical record and EDC but  will not count as related 
to the study device or procedure.   
8.1.1 Definitions  
Following are definitions associa ted with AEs: 
Adverse Event - any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal  laboratory or  image 
findings) in participants, users or other persons, whether or not related to the 
investigational medical device and whether anticipated or unanticipated (per ISO 14155) 
Note: This definition includes events related to the investigational medical 
device or the comparator . This definition also includes events related to the 
procedures involved. For users or other persons, this definition is restricted to 
events related to the use of investigational medical devices.   
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 43 of 60  CONFIDENTIAL  
Serious Adverse Event  (SAE)  - an adverse event that led to any of the following 
(per ISO 14155) 
a) death, 
b) serious deterioration in the health of the p articipant, users or other 
persons as defined by one or more of the following:  
1) a life -threatening illness or injury,  or 
2) a permanent impairment of a body structure or a body function 
including chronic disease, or  
3) in-patient or prolonged hospitalization,  or 
4) medical or surgical intervention to prevent life -threatening 
illness or injury or permanent impairment to a body structure or 
a body function, 
c) fetal distress, feta l death, or a congenital abnormality, or birth defect 
including physical or mental impairment. 
Note : Planned hospitalization for a pre -existing condition, or a procedure 
required by the protocol, without serious deterioration in health, is not considered a serious adverse event.  
Adverse Device Effect (ADE)  – adverse event related to the use of an 
investigational medical device.  
Note : This definition includes adverse events resulting from insufficient or 
inadequate instructions for use , deployment , implantation, installation, or 
operation, or any malfunction of the investigational medical device. This 
definition also includes any event resulting from use error or from intentional misuse of the investigational medical device. This includes  comparator if the 
comparator is a medical device  
Serious Adverse D evice  Effect (SADE)  – an adverse device effect that has 
resulted in any of the consequences characteristic of a serious adverse event  
(per ISO 14155). 
Unanticipated Adverse Device Effect ( UADE)  - any serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or 
associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the inve stigational plan 
or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of participants (21 CFR 812.3(s)). 
Relationship to device an d procedure 
The potential relationship of the event to the device or procedure  will be 
categorized by the investigator as follows: 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 44 of 60  CONFIDENTIAL  
• Not related  
An adverse event for which sufficient information exists to indicate that 
there is no causal connection between t he event and the device or 
procedure. The adverse event is due to and readily explained by the 
participant’s underlying disease state or is due to concomitant 
medication or therapy not related to the use of the device or the procedure. In addition, the adverse event may not follow a reasonable temporal sequence following the procedure.  
• Unlikely  
The relationship with the use of the device or procedure seems not relevant and/or the adverse event can be reasonably explained by 
another cause, but additional information may be obtained.  
• Possibly related  
There is a reasonable possibility that the adverse event may have been primarily caused by the device  or procedure. The adverse event has a 
reasonable temporal relationship to the use of the device or the procedure and follows a known or expected response pattern to the device or procedure, but alterna tive etiology is equally or more likely 
compared to the potential relationship to the use of the device or the 
procedure. 
• Probably related 
There is a reasonable probability that the adverse event may have been primarily caused by the device or procedure. T he adverse event has a 
reasonable temporal relationship to the use of the device or the procedure and follows a known or expected response pattern to the device or procedure , and an alternative etiology is unlikely or 
significantly less likely . 
• Definitely related  
The adverse event has a strong causal relationship to the device or procedure. The adverse event follows a strong temporal relationship to the use of the device or the procedure, follows a known response pattern to the device or procedure, and cannot be reasonably explained by known characteristics of the participant’s clinical state or other therapies.  
Every effort should be made to determine the cause of each adverse event, because a judgment must be made as to the relationship to the device or procedure. If an investigator cannot assign a causality category the event will 
be considered possibly related for reporting and analysis.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 45 of 60  CONFIDENTIAL  
Note : The occurrence of a diagnostic or elective surgical procedure for a pre-
existing condition, unless the condition becomes more severe or increases in 
frequency, would not be considered procedure- or device- related.  
Intensity of adverse events :  
• Mild  
The adverse event is noticeable to the participant but does not interfere with routine activity.  
• Moderate  
The adverse event interferes with routine activity but responds to symptomatic therapy or rest. 
• Severe  
The adverse event significantly limits the p articipant's ability to perform 
routine activities despite symptomatic therapy. The adverse event requires medical or surgical treatment or results in hospitalization.  
8.1.2 Documentation and Reporting of Adverse Events  
All adverse events will be monitored from the time of study entry  through study 
exit. All adverse events must be reported on the Adverse Event Report eCRF. A description of the event, including onset date, resolution date, action taken, and the outcome should be provided. All adverse events will be followed until they a re adequately resolved or reach a chronic, stable state.  If a p articipant 
reaches the 36 -month follow -up visit and is experiencing a new or ongoing 
adverse event, the sponsor should be contacted to discuss the need and/or methods for continued surveillance of the event. Adverse events will be evaluated by the investigator and differentiated by: 
• Seriousness 
• Intensity  (mild, moderate, severe)  
• Causality (in relation to the device or procedure) 
• Unexpectedness  
Signs and symptoms considered normal postprocedure  recovery (eg, 
postprocedure pain, transient sensory symptoms, fever, postanesthesia symptoms) do not have to be reported as adverse events. If these events require treatment outside that which is considered normal or if the event lasted longer 
in duration than normal, they should be reported as adverse events.   
All adverse events classified as an Unanticipated  Adverse D evice E ffect , 
Serious Adverse Device Effect, or Serious  Adverse Event  must  be reported 
to the s ponsor  within 24 hours of learning of the e vent.  
Sponsor Contact: Anais Laborde   
Phone: 650-518-9624 
Email: alaborde@aerinmedical.com
  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 46 of 60  CONFIDENTIAL  
Investigators must also report promptly all unanticipated problems to their 
IRB/EC and/or regulatory authority involving risks to participants or others and report adverse events according to the local or national reporting requirements. Reporting instructions and contact information will be provided in the site’s Regulatory Binder for this study.  
8.2 Product Complaints  / Device Deficiencies  
8.2.1 Definitions  
Product Complaint  - Any written, electronic or oral communication that alleges 
deficiencies related  to the identity, quality, durability, reliability, safety, 
effectiveness, or performance of an Aerin product (medical device) after it is released for distribution (per 21 820.3(b)). 
Complaint – written, electronic or oral communication that alleges defic iencies 
related to the identity, quality, durability, reliability, usability, safety or performance of a medical device that has been released from the organization's control or related to a service that affects the performance of such medical device (per ISO 13485). 
Reportable Complaint  – Any product complaint that represents an event, which 
must be reported to a regulatory agency including: 
• US F DA (per 21 CFR Part 803) 
• A Competent Authority within the European Community or a Notified 
Body ( MDD) 
• The Canadi an HPFB  
• Any regulatory agency, within the country of distribution 
Device Deficiency  – inadequacy of a medical device with respect to its 
identity, quality, durability, reliability, usability, safety or performance.  
Note: Device deficiencies include malfunctions, use errors, and inadequacy in 
the information supplied by the ma nufacturer including labeling. This 
definition includes device deficiencies related to the investigational medical device or the comparator (per ISO 14155) . 
8.2.2 Documentation and Reporting of Complaints  / Device Deficiencies  
All product complaints, deficiencies and malfunctions associated with devices 
will be documented on the appropriate e CRF  and/or communicated to the 
sponsor within 24 hours of first becoming aware of the event.  
9.0 Study Administration  
This study will be conducted in accordance with elements of I CH E6 Guideline for  
GCP , Abbreviated Requirements of 21 CFR 812 for nonsignificant risk device studies, 
the European Standard ISO 14155, the Declaration of Helsinki, the Belmont Report , 
and any applicable regional or national regulations. 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 47 of 60  CONFIDENTIAL  
The sponsor has the overall responsibility for the conduct of the study according to all 
applicable regulatory requirements. The sponsor will have certain direct responsibilities and will delegate other responsibilities to the investigator and study site. The sponsor and investigator  will ensure that the study is conducted according to 
all applicable regulations. All personnel participating in the conduct of this study will 
be qualified by education and experience to perform their tasks. 
The sponsor, treating physician, or any person acting for or on behalf of the sponsor or 
investigator shall act in accordance the applicable standards, guidelines and 
regulations. This study is funded by Aerin Medical. The Clinical Trial Agreement (CTA), mutua lly 
signed by the study site  and Aerin Medical, describes t he agreement between sponsor 
and site with respect to study financing. 
9.1 Investigator Training  
Site initiation training will occur prior to the first procedure at a site. Investigators 
will be trained  on the procedure and use of the Vivaer ARC Stylus  and Aerin Console.  
All study staff will be trained, as necessary, to ensure compliance with the protocol and regulatory requirements , as well as to ensure accurate data collection. S ite 
training will include a detailed review of this protocol, use of the EDC system, eCRF 
completion instructions, adverse event reporting, product handling and inventory, 
monitoring logistics, and regulatory requirements. 
9.2 Study Monitoring  
Study monitoring will be carried out in compliance with FDA regulations, ISO 14155, and Good Clinical Practice (GCP) guidelines. The monitoring for this study 
will be carried out by monitors qualified by experience and training who are Aerin Medical employ ees or individuals contracted by Aerin to conduct monitoring 
activities. The study monitors will oversee the conduct of the study either on -site or 
remotely and evaluate compliance with the protocol, any specific recommendations made by the site’s IRB and the signed Investigator Agreement. During the study, phone contacts and site visits will be conducted to ensure protocol compliance. Monitoring will include a verification the informed consent was properly obtained for all study participants, a review of clinical records for accuracy and completeness, 
resolution of missing or inconsistent results, a review of source documents, and ensuring adverse events, protocol deviations and device usage are properly documented. The monitor will conduct source data verification by verifying eCRFs are consistent with source documents. The investigator will make available to the monitor for review the informed consent forms, source documents, and any other relevant records for all study participants at the site. The invest igator and other site 
personnel will be accessible to the monitor during visits whether on -site or remote 
and sufficient time is provided to conduct the visits and address questions. If the monitor becomes aware of any deficiencies during the course of the  study, the 
monitor will discuss with the sponsor and investigator to ensure compliance is maintained. A final close -out monitoring visit will occur when the study has been 
completed or terminated.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 48 of 60  CONFIDENTIAL  
9.3 Documentation of Study Findings  
9.3.1 Data Management 
A secure E DC and management system will be used for entry, storage, review, 
and management of study data. The system will use the Medrio EDC platform 
(Medrio, Inc. San Francisco, CA) and be compliant with applicable GCP and 
regulatory requirements. Investi gators are responsible for accurate completion 
and timely submission of the data collected during the study. Sites will be trained in the use of the system for entering study data and uploading supporting documents and will be given access for this purpose . Data monitoring will be 
performed to identify missing data, verify data accuracy , and ensure queries are 
resolved. Any data issues are to be promptly addressed with the investigator. 
Quality assurance procedures will be established  to ensure that complete, 
accurate and t imely data are submitted, p rotocol requirements are followed, and 
that complications, adverse events and adverse device effects are correctly 
reported and investigated as appropriate . The management and retention of 
these data will be compliant with applicable regulatory requirements.   
9.3.2 Case Report Forms  
Standardized electronic case report forms (eCRFs) will be used at all 
participating study sites to collect complete and accurate records of the clinical data. All study data will be entered by study personnel through eCRFs for each participant screened in the study. A unique ID number will be assigned to each 
participant.  
The following eCRFs  and logs will be used in this study and submitted at the 
intervals outlined in Table 1: 
• Screening Visit  / Study Eligibility  (01) 
• ICF Checklist (01A) 
• Screening Visit – Demographics, Treatment History  & Nasal Exam  
(02) 
• CT Settings Checklist (02A) (selected sites only ) 
• NOSE  Scale ( 03) 
• NRS Ease of Breathing – Participant form (04)  
• SNOT -22 (05) 
• Preprocedure (06A) 
• Anesthesia and Procedure (06B) 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 49 of 60  CONFIDENTIAL  
• Immediate Post procedure (06C)  
 
• VAS for nasal pain – Participant form (07 A) 
• VAS for nasal pain – Site form (07B) 
• Follow-up Visit (08)  
• Participant Satisfaction Survey (09) 
• Study Exit (10)  
• Device Malfunction Report (1 1) 
• Protocol Deviation (12)  
• Adverse Event Report (13A) (reference AE Code List [13B ]) 
• Serious Adverse Event / Unanticipated Adverse Device Effect  
• (SAE / UADE)  Report (1 4) 
• Medication Log (15) 
• Unscheduled Visi t (16)  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 50 of 60  CONFIDENTIAL  
Table 1.  Schedule of case report forms and related materials . 
Visit  Visit Window 
(days)  eCRF  Other  
Screening  n/a 01, 01A, 02, 
02A*, 03, 04, 05, 15 Informed Consent  
Nasal assessment images† 
CT imaging * 
Study Procedure  
(preprocedure/anesthesia/treatment)  within 30 days of 
Screening  06A, 06B,  Nasal assessment images† 
Nasal assessment does not 
get repeated  Preprocedure  
if the Screening and 
Treatment visits occur on 
the same day  
 
Postprocedure  0 06C, 07A, 07B, 15 Nasal assessment images† 
1-Week  (In-office)  +3 07A, 07B, 08, 15  Nasal assessment images† 
13-Week  (In-office)  ±14 02A*, 03, 04, 05, 
08, 09, 15  Nasal assessment images† 
CT imaging * 
6-Month (Remote)  ±30 03, 04, 05, 08, 09, 
15  
12-Month (Remote)  ±30 03, 04, 05, 08, 09, 
15   
24-Month (Remote)  ±30 03, 04, 05, 08, 09, 
15  
36-Month (Remote)  ±30 03, 04, 05, 08, 09, 
10, 15   
As Needed  n/a 10, 11, 12, 13 A, 
13B, 14, 16  
†Copy de -identified endoscopic video/images collected for study records to USB flash drive and provide to Sponsor. 
*Sites selected for substudy only  
 
 9.3.3 Investigator Responsibilities, Records, and Reports  
Responsibilities 
The investigator is responsible for ensuring that the study is conducted according to the protocol and all IRB requirements. In addition, the investigator is responsible for obtaining participant’s written informed consent and written authorization for disclosure and use of health information as required under the Health Insurance Portability and Accountability Act (HIPAA); 45 CFR Parts 160 and 164), or other documentation as required by the IRB and national regulations. 
Records 
The investigator will mainta in complete, accurate and current study records.  
Investigator records including: 
1. Relevant communication that documents any agreements or significant discussions regarding trial administration, protocol violations, trial conduct, or adverse event reporting, including that with th e IRB, the 
sponsor , the study monitors , other investigators, and regulatory 
agencies.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 51 of 60  CONFIDENTIAL  
2. Participant records, including the participant’s informed consent form, 
case history, procedure dictation, adverse events, progress notes, 
follow -up evaluations, case report forms and all supporting documents, 
such as diagnostic studies.  
3. Study protocol, amendments, and documentation (dates and reasons) of 
any deviations from the protocol.  
4. IRB records, including original and ongoing study approval s, all 
correspondence, and the approved informed consent form (s). 
5. IRB membership list, Federal Wide Assurance for the Protection of Human participants (FWA) as applicable, statement of compliance and written procedures pertaining to AE and Protocol Deviation reporting (if available).  
6. Study agreement, curricula vitae of investigator(s), financial disclosure, signature authorization log (deleg ation of responsibility), protocol 
signature page, and participant screening/enrollment log.  
7. Reports (including safety reports, progress  reports and a final report 
from the investigator). 
8. Any other records, as required by the IRB and the sponsor. 
Reports 
Investigators are required to prepare and submit the following reports in a  
complete,  accurate, and timely fashion: 
1. In the event of an adverse experience that is serious or unanticipated, or which requires action by s ponsor to prevent an unreasonable risk of 
substantial harm to public health, notice shall be given immediately (but in no event later than 24 hours after learning of such experience) by telephone or email to the sponsor and the IRB. Any notices made by 
telephone shall be confirmed in wr iting within 2 days of the initial 
notification. The site shall provide all associated documentation ( eg, lab 
reports, death summary, operative reports, etc.) for each adverse experience.  
2. Unanticipated adverse device effects and serious a dverse events should 
be reported to the sponsor within  24 hours of event discovery. If the 
adverse event is alarming, the investigator shall report the event immediately.  
3. Investigators shall promptly report to the IRB all changes in the research activity and all unanticipated problems involving risk to participants and others, and that s/he will not make any changes in the research without 
IRB approval, except where necessary to eliminate apparent hazards to 
the participants.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 52 of 60  CONFIDENTIAL  
4. Withdrawal of IRB approval reported to the sponsor within 5 working 
days. The report will include a complete description of the reason that 
approval was withdrawn. 
5. Progress reports must be submitted to the IRB at regular intervals 
dictated by the IRB /EC but no less than annually. 
6. A final report must  be submitted to the IRB within 3 months after 1) 
termination or completion of the study; or 2) the i nvestigator's work on 
the study ceases.  
7. Any deviation from the protocol to protect the life or physical well -
being of a p articipant in an emergency is to b e reported to the sponsor 
and IRB no later than 5 working days after the emergency occurs.  
Deviations to the informed consent process (eg, use of study product without informed consent) must be reported to the sponsor and the IRB immediately but no later than 5 working days after the use occurs. Deviations from the randomization scheme must be reported to the sponsor as soon as possible after they are recognized.  
8. Other: upon request, the i nvestigator will supply accurate, complete and 
current information a bout any aspect of the s tudy to the sponsor. 
9.3.4 Retention of Study Records  
The sponsor must ensure that all study participant records are stored for at least 2 years after the later of the following 2 dates: the date on which the study is terminated or completed (all study participants through final follow -up), or the 
date that the records are no longer required by the  study site record retention 
policy or per applicable regulatory requirements. To avoid error, the site should contact the sponsor prior to the destruction of study records to ensure that they no longer need to be retained. In addition, the sponsor should be contacted if the study site is acquired or shuts down so that arrangements can be made for the handling or transfer of study records. 
9.3.5 Data Quality Assurance 
The sponsor, or the sponsor’s representative, may conduct audits at the study sites. Audit s may include, but are not limited to, device supply, presence of 
required documents, the informed consent process, and comparison of eCRFs 
with source documents. The investigator agrees to participate with audits conducted at a reasonable time, in a reaso nable manner. 
9.3.6 Confidentiality  
All information provided to investigators, IRBs, and generated in this study must be considered highly confidential and must not be disclosed to any persons 
not directly involved with the study without prior written permission from the 
sponsor. However, authorized regulatory officials and sponsor personnel (or their representatives) will be allowed full access to inspect and copy the records. All study products must be used solely in accordance with this protocol. Privacy 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 53 of 60  CONFIDENTIAL  
and confidentiality of information about each p articipant shall be preserved in 
the reports and in any publication. Each participant in this study will be assigned 
a unique identifier. All data will be tracked, evaluated, and stored using only this unique identifier.  
The study site will maintain a confidential list (paper or electronic) identifying all participants. This list will contain the assigned participant’s unique identifier 
and name. The investigator is responsible for keeping this list confidential. This list will not be provided to the study sponsor and is only to be used at the study site. 
Monitors and auditors will have access to the study participant list and other personally identifying information of participants to ensure that data reported corresponds to the person who signed the informed consent form and the information contained in original source documents. Such personal identifying information may include, but is not limited to the participant’s name, address, date of birth, gender, race and medical record number.   
9.3.7 Publication Policies  
The CTA,  mutually signed by the investigator(s) and Aerin Medical, defines 
and describes the nature of the study agreement. The data and results from this study are the sole property of Aerin Medical. Aerin Medical shall have the righ t 
to access and use all data and results generated during the clinical investigations  
now and in the future for presentation or publication at the sponsor’s discretion or for submission to governmental agencies. Publication authorship will be established according to the International Committee of Medical Journal 
Editors  (ICMJE ) guidelines and Aerin Medical policy. Clinical study design 
will be publicly disclosed on ClinicalTrials.gov, and summary results posted per FDAAA 801 Requirements, and in accordance with national regulations as required by other regulatory agencies . Additionally, an i nvestigator may only 
publish data generated by this trial in accordance with the terms of the CTA.  
It is Aerin Medical’s intent to encourage and facilitate the publications of 
scientifically important results, while simultaneously ensuring minimization of  
duplicative data publication and the priority publications of multicenter results ahead of single- center investigations.  
Aerin Medical intends to provide research sites with a standardized  study report 
containing aggregated site study data. 
9.4 Study Sus pension or E arly Termination 
The study can be suspended or discontinued at the discretion of the s ponsor for 
reasons including, but not limited to, the following: 
• Obtaining new scientific knowledge that shows that the study is no longer valid or necessary . 
• Insufficient recruitment of participants.  
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 54 of 60  CONFIDENTIAL  
• Unanticipated adverse device effect presenting an unreasonable risk to 
participants.  
• Persistent noncompliance with the protocol and/or IRB or regulatory 
authority requirements. 
If the study is disc ontinued or suspended prematurely, the sponsor shall promptly 
inform all participating study sites and treating physicians of the termination or suspension and the reason(s) for the termination or suspension. The IRB shall also be informed promptly and provided with the reason(s) for the termination or suspension by the sponsor. The investigator shall promptly inform screened participants at 
his/her study site, if appropriate. Regulatory authorities and the personal physicians of the participants may also n eed to be informed if deemed necessary. All applicable 
study documents will be participant to the same retention policy as detailed in Section 
9.3.3 
10.0 Ethics  
10.1 Institutional Review Board  
This study may not be initiated at a site until applicable Institutional Review Board, or regulatory authority approval/favorable opinion is obtained. The study protocol, all study protocol amendments, written study participant information, informed consen t form, and any other appropriate study- related information must be reviewed 
and approved by the IRB. Any additional requirements or conditions imposed by the IRB or regulatory authority shall be followed, if appropriate. 
To assure proper review and study oversight, the IRB  must comply with the 
responsibilities, functions, and records requirements defined in U.S. FDA regulations 
(21 CFR Part 56) or per their regulatory authority . 
The investigator at each site is responsible for submitting the appropriate st udy 
documentation to the IRB for review and approval in accordance with applicable  
regulations. The investigator is responsible for providing accurate, complete, and 
current information to the IRB  throughout the course of the study.  
10.2 Ethical Conduct o f the Study  
The study will be conducted in accordance with the protocol, GCP, and all applicable regulatory requirements governing clinical studies of marketed products. Compliance with these requirements also constitutes conformity with the ethical principles that have their origin in the Declaration of Helsinki and the rights, safety and well -being 
of study participants shall be protected consistent with these principles.  
The sponsor will promptly review all information relevant to the safety of the product that is received and comply with all regulatory device safety reporting requirements .  
10.3 Participant Privacy  
The privacy of participants in this study will be protected by all reasonable means.  
The investigator is responsible for study records at the study site and must only disclose information as provided for in the site’s Authorization to Use and Disclose 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 55 of 60  CONFIDENTIAL  
Health Information. Each participant must give permission for use and disclosure of 
their information by signing the Authorization to Use and Di sclose Health 
Information. This form may be a separate document from the informed consent form, 
or it may be contained within or as an addendum to the informed consent form. Although the sponsor is not a covered entity under HIPAA, access to study records,  
particularly participant information, will be strictly limited by the sponsor to the 
investigator, the sponsor’s clinical research personnel, authorized representatives of the sponsor, the FDA under applicable federal regulations, or other regulatory authority as required per national regulations. No public reporting or publications of the results of this study will contain identifiable references to individual participants 
in the study. 
10.4 Participant Insurance  
It is the responsibility of the sponsor to provide insurance covering the cost of treatment of participants in the event of clinical- investigation -related injuries, in 
accordance with the national regulations, as applicable.  
10.5 Participant Reimbursement  
Participants may be reimbursed for their time for completing questionnaires as 
allowed by the IRB and study site policies. Participants will not be reimbursed for questionnaires not completed. 
10.6 Participant Withdrawal 
Participants may voluntarily withdraw from the study at any time for any reason 
without impact to their future medical care at the study site. In addition, the investigator may withdraw a participant from the study, if in the investigator’s opinion, it is not in the best interest of the participant to continue in the study. Any 
participant withdrawing from the study for any reason will continue to receive medically necessary follow -up care as determined by the investigator. Every attempt 
should be made to follow a participant w ithdrawing either because they failed to 
obtain a desired effect or suffered an adverse event.  
When a participant chooses to withdraw, the investigator or designee will make all possible efforts to collect and report the final visit observations. If the investigator has made 3 documented attempts to contact the participant and received no response, the participant may be considered to be lost to follow -up. A participant who misses a 
study visit but attends a subsequent visit will no longer be considered los t to follow -
up. All reasons for withdrawals and documentation will be recorded in source documentation and the appropriate case report form. In addition, within the informed consent process, participants will be asked to provide consent for the study staff  to 
contact them by mail or phone to follow up on safety- related issues as appropriate.  
10.7 Protocol Modifications  
This protocol shall not be amended without the approval of the sponsor. The sponsor may amend the protocol to clarify study procedures or to implement changes to the 
protocol that do not affect the validity of the data; the risk to benefit ratio; the 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 56 of 60  CONFIDENTIAL  
scientific soundness of the protocol; or the rights, safety, or welfare of the 
participants. All modifications must be reviewed and approved by t he IRB before 
implementation.   
10.8 Protocol Adherence and Deviations  
10.8.1 Definition  
Deviation – instance of failure to follow, intentionally or unintentionally, the 
requirements of the protocol (per ISO 14155). 
10.8.2 Documentation and Reporting of Deviations 
The investigator(s) agree to conduct the study in accordance with this protocol. 
An investigator must not make any changes in the study without first receiving agreement by the sponsor and approval in writing from the IRB, except when necessary to eliminate apparent immediate hazards to a participant. 
Investigators will also adhere to procedures for reporting study deviations to their IRB in accordance with their specific IRB reporting policies and procedures. Deviations will also be reported to the regulatory authority as 
required per national regulations.  
Deviations must be reported to the sponsor regardless of whether medically 
justifiable, preapproved, or performed to protect the participant in an emergency. The investigator will document and explain the reason for the 
deviation. p articipant deviations will be reported using the Protocol Deviation 
eCRF.   
 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 57 of 60  CONFIDENTIAL  
11.0  References  
 
1. Udaka T, Suzuki H, Kitamura T, et al.  Relationships among nasal obstruction, 
daytime sleepiness, and quality of life. Laryngoscope  2006;116(12):2129-2132. 
2. Rhee, JS, Book DT, Burzynski  M, Smith  TL. Quality of life assessment in nasal 
airway obstruction. Laryngoscope  2003;113(7):1118-1122.  
3. Rhee JS, Weaver EM, Park SS, et al. Clinical consensus statement: Diagnosis and 
management of nasal valve compromise. Otolaryngol Head Neck Surg 
2010;143(1):48-59.  
4. Recker C, Hamilton G. Evaluation of the patient with nasal obstruction. Facial 
Plast Surg 2016;32(1):3-8. 
5. Chandra R, Patadia M, Raviv J. Diagnosis of nasal airway obstruction. 
Otolaryngol Clin North Am  2009;42(2):207-225, vii. 
6. Wittkopf M , Wittkopf J, Ries WR. The diagnosis and treatment of nasal valve 
collapse. Curr Opin Otolaryngol Head Neck Surg 2008;16(1):10 -13. 
7. Fraser L. , Kelly G.  An evidence-based approach to the management of the adult 
with nasal obstruction. Clin Otolaryngol  2009;34(2):151- 155. 
8. Cole P. The four components of the nasal valve. Am J Rhinol  2003;17(2):107-
110. 
9. Barrett D, Casanueva F, Cook T. Management of the nasal valve. Facial Plast 
Surg Clin North Am  2016;24(3):219-234. 
10. Wexler DB, Davidson TM. The nasal valve: a review of the anatomy, imaging, 
and physiology. Am J Rhinol  2004;18(3):143-150. 
11. Bloching MB . Disorders of the nasal valve area.  GMS Curr Top 
Otorhinolaryngol Head Neck Surg 2007;6:Doc07. 
12. Kirkness JP, Wheatley JR,  Amis TC. Nasal airflow dynamics: mechanisms and 
responses associated with an external nasal dilator strip. Eur Respir J 2000;15(5):929-936. 
13 Peltonen LI, Vento SI, Simola  M, Malmberg H. Effects of the nasal strip and 
dilator on nasal breathing --a study with healthy subjects. Rhinology  
2004;42(3):122-125. 
14. Roithmann R , Chapnik J, Cole  P, et al.  Role of the external nasal dilator in the 
management of nasal obstruction. Laryngoscope  1998;108(5):712-715. 
15. Ellegard E. Mechanical nasal alar dilators. Rhinology  2006;44(4):239-248. 
16. Khosh MM, Jen A, Honrado C, Pearlman SJ. Nasal valve reconstruction: experience in 53 consecutive patients. Arch Facial Plast Surg 2004;6(3):167-171. 
 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 58 of 60  CONFIDENTIAL  
 
17. Fischer H, Gubisch W. Nasal valves --importance and surgical procedures. Facial 
Plast Surg 2006;22(4):266-280.  
18. Spielmann PM, White PS, Hussain SS. Surgical techniques for the treatment of 
nasal  valve collapse: a systematic review. Laryngoscope 2009;119(7):1281-1290. 
19. Rhee J, Arganbright J, McMullin B, Hannley M. Evidence supporting functional rhinoplasty or nasal valve repair: A 25- year systematic review. Otolaryngol Head 
Neck Surg  2008;139(1):1020. 
20. Stolovitzky P, Senior B, Ow RA, et al. Assessment of bioabsorbable implant treatment for nasal valve collapse compared to a sham group: a randomized control trial. Int Forum Allergy Rhinol  2019;9(8):850-856. 
21. Sapci T, Sahin B, Karavus A, Akbulut UG. Comparison of the effects of radiofrequency tissue ablation, CO2 laser ablation, and partial turbinectomy applications on nasal mucociliary functions. Laryngoscope  2003;113(3):514-
519. 
22. Coste A, Yona L, Blumen M, et al. Radiofrequency is a safe and effective 
treatment of turbinate  hypertrophy. Laryngoscope  2001;111:894-899. 
23. Sapçı TM , Güvenç G , Evcimik  MF. Radiofrequency treatment for inferior 
turbinate hypertrophy. Kulak Burun Bogaz Ihtis Derg 2011;21(1): 6-60. 
24. Hytonen ML, Back LJ, Malmivaara AV, Roine RP. Radiofrequency thermal ablation for patients with nasal symptoms: a systematic review of effectiveness 
and complications. Eur Arch Otorhinolaryngol  2009;266(8):1257-1266. 
25. Seren E. A new surgical method of dynamic nasal valve collapse. Arch Otolaryngol Head Neck Surg 2009;135(10):1010-1014. 
26. Jacobowitz O, Driver M, Ephrat M. In- office treatment of nasal valve obstruction 
using a novel, bipolar radiofrequency device. Laryngoscope Investig Otolaryngol  
2019;4(2):211-217. 
27. Ephrat M, Jacobowitz O, Driver M . Quality -of-life impact after in -office 
treatment of nasal valve obstruction with a radiofrequency device: 2 -year results 
from a multicenter, prospective clinical trial. Int er Forum Allergy Rhinol  
2020;00:1 -11 (online). 
28. Wotman M , Kacker A. Should otolaryngologists pay more attention to nasal 
swell bodies? Laryngoscope  2015;125(8):1759-1760. 
29. Patrascu  E, Budu V , Musat G.  Nasal swell body: a literature review . Rom J Rhinol  
2020;10(37): 19-23.
 
30 Wustrow F. Septal turbinate. Zeitschrift Anatomic Entwicklungsgeschichte 1951; 116: 139-142. 
 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 59 of 60  CONFIDENTIAL  
 
31. Costa DJ, Sanford T, Janney C, et al . Radiographic and a natomic characterization 
of the nasal septal swell body. Arch Otolaryngol Head Neck Surg  
2010;136(11):1107-1110. 
32. Lee SJ , Lee ES. Nasal septal swell body: Radiologic c haracteristics and the 
relationship to nasal septal deviation. Korean J Otorhinolaryngol -Head Neck 
Surg 2016;59(7):517-521.  
33. Gelera JE, Ojar D, Lim JH,  et al. Radiographic changes of the nasal septal body 
among patients with sinonasal diseases. Clin Exp Otorhinolaryngol  
2017;10(4):38-343. 
34. Wustenberg EG, Scheibe M, Zahnert T, Hummel T. Different swelling 
mechanisms in nasal septum (Kiesselbach area) and inferior turbinate responses to histamine: an optical rhinometric study. Arch Otolaryngol Head Neck Surg. 2006; 132: 277-281. 
35. Ng BA, Ramsey RG, Corey JP. The distribution of nasal erectile mucosa as visualized  by magnetic resonance imaging. Ear Nose Throat J  1999;78(3):159-
166. 
36. Catalano P, Ashmead MG, Carlson D. RadioFrequency a blation of s eptal swell 
body. Ann Otolaryngol Rhinol 2015;2(11):1069. 
37. Kim SJ, Kim HT, Park YH, Kim JY, Bae JH. Coblation nasal septal swell body reduction for treatment of nasal obstruction: a preliminary report. Eur Arch Otorhinolaryngol 2016;273(9):2575-2578. 
38. Stewart MG , Smith TL. Objective versus subject ive outcomes assessment in 
rhinology. Am J Rhinol  2005;19(5):529-535. 
39. Lam DJ, James KT,  Weaver EM. (2006). Comparison of anatomic, physiological, 
and subject ive measures of the nasal airway. Am J Rhinol  2006;20(5):463-470. 
40. Andre RF, Vuyk HD, Ahmed A et al. Correlation between subject ive and 
objective evaluation of the nasal airway. A systematic review of the highest level of evidence. Clin Otolaryngol  2009;34(6):518- 525. 
41. Dadgarnia MH, Baradaranfar  MH, Mazidi M,  Azimi Meibodi SM . Assessment 
of septoplasty e ffectiveness using a coustic rhinometry and rhinomanometry. Iran 
J Otorhinolaryngol  2013;25(71):71-78. 
42. Andrews PJ, Choudhury N , Takhar  A, et al.  The need for an objective measure 
in septorhinoplasty surgery: are we any closer to finding an answer? Clin Otolaryngol  2015;40(6): 698-703. 
43. Stewart MG, Witsell DL, Smith TL, et al . Development and validation of the 
Nasal Obstruction Symptom Evaluation  (NOSE) scale. Otolaryngol Head Neck 
Surg 2004;130(2):157-163. 
 
  CTP1125 Rev C 
Clinical Study Protocol – SWELL Study    
 
 Page 60 of 60  CONFIDENTIAL  
 
44. Lipan MJ, Most SP. Development of a severity classification system for 
subjective nasal obstruction. JAMA Facial Plast Surg 2013;15(5):358- 361 
45. Scott J, Huskisson EC.  Graphic representation of pain. Pain  1976;2:175-184. 
46. Anderson ER, Murphy MP, Weymuller Jr EA. Clinimetric evaluation of the Sinonasal Outcome Test -16. Otolaryngol. Head Neck Surg 1999;121(6):702–
707. 
47. Hopkins C, Gillett S, Slack R, et al. Psychometric validity of the 22 -item 
Sinonasal Outcome Test. Clin Otolaryngol  2009;34(5):447-454. 
48. Browne JP, Hopkins C, Slack R, Cano SJ. The Sino- Nasal Outcome Test 
(SNOT): can we make it more clinically meaningful? Otolaryngol Head Neck 
Surg 2007;136(5):736-741. 
49. Soler ZM, Jones R, Le P, et al. Sino- Nasal outcome test -22 outcomes after sinus 
surgery: A systematic review and meta- analysis. Laryngoscope  2018;128(3):581-
592. 
50. DeConde AS, Bodner TE, Mace JC, Smith TL. Response shift in quality of life after endoscopic sinus surgery for chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg . 2014;140(8):712-719. 
 